Transplant Diagnostics Market by Product & Service (Instrument, Software), Technology (PCR, NGS), Application [Diagnostic (Infectious Disease, HLA) Research], Type [Solid Organ (Heart), Bone Marrow], End User (Hospital) & Region -Global Forecast to 2031

icon1
USD 8.14 BN
MARKET SIZE, 2031
icon2
CAGR 7.8%
(2026-2031)
icon3
499
REPORT PAGES
icon4
500
MARKET TABLES

OVERVIEW

global-transplant-diagnostics-market Overview

Source: Secondary Research, Interviews with Experts, MarketsandMarkets Analysis

The transplant diagnostics market is expected to reach USD 8.14 billion by 2031 from USD 5.61 billion in 2026, at a CAGR of 7.8% during the forecast period. The primary factors driving the growth of this market include the increasing number of organ transplantation procedures and the rising prevalence of chronic diseases requiring transplantation. The growing demand for accurate donor-recipient compatibility testing, histocompatibility testing, infectious disease testing, and blood profiling is further supporting market growth. Increasing research and development investments have resulted in significant advancements in molecular diagnostic technologies, including PCR and next-generation sequencing (NGS). Other major growth drivers include rising public and private investments and increasing government initiatives aimed at strengthening transplantation and diagnostic infrastructure.

KEY TAKEAWAYS

  • BY REGION
    By region, North America leads the market in 2025.
  • BY PRODUCT & SERVICE
    By product & service, the reagents & consumables segment is expected to register the highest growth rate during the forecast period.
  • BY TECHNOLOGY
    By technology, the molecular assays segment held the largest market share of 89.7% in 2025.
  • BY APPLICATION
    By application, diagnostic applications are expected to grow at the highest CAGR during the forecast period.
  • BY TYPE
    By type, solid organ transplantation leads the market with a share of 90.9% in 2025.
  • BY END USER
    By end user, independent reference laboratories are expected to grow at the highest rate.
  • COMPETITIVE LANDSCAPE - KEY PLAYERS
    Thermo Fisher Scientific Inc. (US), F. Hoffmann-La Roche Ltd. (Switzerland), Bio-Rad Laboratories, Inc. (US), QIAGEN N.V. (Netherlands), and bioMérieux (France) were identified in the transplant diagnostics market as star players, which correspondingly is supported by their strong market presence and extensive product portfolios.
  • COMPETITIVE LANDSCAPE - STARTUPS/SMEs
    Scisco Genetics, Inc. (US), inno-train Diagnostik GmbH (Germany), Bionobis (France), Takara Bio Inc. (Japan), Krishgen Biosystems Private Limited (India), and Prolmmune Ltd. (UK)have distinguished themselves among startups and SMEs by securing strong footholds in specialized niche areas.

The transplant diagnostics market is expected to witness significant growth due to the increasing number of transplant procedures and the rising prevalence of infectious diseases requiring accurate donor-recipient compatibility testing. Molecular diagnostic technologies, including PCR and next-generation sequencing (NGS), have experienced rapid advancements and are contributing to improved efficiency, accuracy, and turnaround time of transplant diagnostic procedures. Furthermore, increasing public-private funding and growing investments in transplant research are supporting research and development activities, which are expected to accelerate the adoption of advanced transplant diagnostic technologies and support market expansion during the forecast period.

TRENDS & DISRUPTIONS IMPACTING CUSTOMERS' CUSTOMERS

The growing number of organ transplantation procedures, along with advancements in molecular diagnostic technologies, has led to an increased demand for transplant diagnostic testing. These diagnostic procedures are essential for assessing donor-recipient compatibility, conducting histocompatibility testing, screening for infectious diseases, and performing blood profiling during transplantation. As techniques such as PCR and next-generation sequencing (NGS) become more widely used, we can expect a higher adoption rate of advanced transplant diagnostic technologies. Additionally, the rise in public and private funding, increased investments in transplant research, and improvements in laboratory technologies are anticipated to enhance the efficiency and accuracy of transplant diagnostic procedures, ultimately supporting market growth.

global-transplant-diagnostics-market Disruptions

Source: Secondary Research, Interviews with Experts, MarketsandMarkets Analysis

MARKET DYNAMICS

Drivers
Impact
Level
  • Increasing number of transplant procedures
  • Advancements in molecular diagnostic technologies
RESTRAINTS
Impact
Level
  • High cost of advanced molecular diagnostic techniques
  • Limited access to advanced transplant diagnostic infrastructure in emerging economies
OPPORTUNITIES
Impact
Level
  • Increasing adoption of cross-matching and chimerism testing
  • Growing awareness regarding organ donation and transplantation
CHALLENGES
Impact
Level
  • Gap between organ donor availability and transplant demand

Source: Secondary Research, Interviews with Experts, MarketsandMarkets Analysis

Driver: Increasing number of transplant procedures

The increasing number of transplant procedures is a significant factor driving the growth of the transplant diagnostics market. The global aging population and the rising prevalence of chronic diseases, such as end-stage renal disease (ESRD), liver cirrhosis, and other organ disorders, are amplifying the demand for organ and tissue transplantation. Recent transplantation statistics indicate that kidney transplants have the highest number of patients on the waiting list, totaling 89,792, followed by liver transplants with 9,424 patients and heart transplants with 3,456 patients. In 2024, over 48,000 transplants were performed. As the number of transplantation procedures and prospective donors grows, there is an increasing demand for donor-recipient profiling, histocompatibility testing, and compatibility testing to minimize the risk of immune rejection.

Restraint: High cost of advanced molecular diagnostic techniques

The high cost of advanced molecular diagnostic techniques is limiting the growth of the transplant diagnostics market. Procedures such as histocompatibility testing, infectious disease testing, and blood profiling require specialized platforms based on PCR and NGS technologies, which are often integrated with automation and microfluidic systems. However, the substantial capital investments and research expenditures associated with these technologies lead to high instrument and procedural costs. This, in turn, increases the financial burden on healthcare providers and patients.

Opportunity: Growing awareness regarding organ donation and transplantation

Growing public awareness about organ donation and transplantation is expected to create significant growth opportunities for the transplant diagnostics market. Organ transplantation is increasingly recognized as an effective treatment option for chronic and terminal diseases such as cancer, chronic kidney disease, and heart disease. The rising prevalence of these conditions is driving the demand for organ transplantation procedures worldwide. Furthermore, the increasing number of patients on organ donation waiting lists and heightened awareness of successful transplantation outcomes are further contributing to market growth. Various governments and public-private organizations in countries such as the US, Japan, Germany, the UK, France, China, and India are undertaking initiatives to promote organ donation. These efforts are anticipated to boost transplantation procedures and increase the demand for transplant diagnostic testing.

Challenge: Gap between organ donor availability and transplant demand

The disparity between the availability of organ donors and the demand for transplants presents a significant challenge for the transplant diagnostics market. The number of patients awaiting organ transplants continues to rise globally, while the annual supply of donated organs remains limited. Statistics indicate that nearly 13 people die each day while waiting for an organ transplant. Several factors contribute to the shortage of organ donors, including strict government regulations, insufficient medical reimbursements for living organ donors, and low public awareness about organ donation, especially in developing countries. Additionally, socio-ethical concerns surrounding deceased organ donation further restrict the availability of organs.

TRANSPLANT DIAGNOSTICS MARKET: COMMERCIAL USE CASES ACROSS INDUSTRIES

COMPANY USE CASE DESCRIPTION BENEFITS
Provides PCR- and sequencing-based transplant diagnostic solutions for compatibility and infectious disease testing. Accurate testing, rapid compatibility assessment, and efficient laboratory workflows.
Offers automated molecular diagnostic and donor screening solutions for transplantation procedures. Fast turnaround time, automated workflows, and high-throughput testing.
Supplies molecular assay technologies and reagents for histocompatibility testing and blood profiling. Reliable testing, improved precision, and efficient laboratory operations.
Provides molecular assays and sample preparation solutions for transplant diagnostics. Efficient sample processing, accurate testing, and streamlined workflows.
Offers molecular diagnostic and infectious disease testing solutions for transplantation procedures. Rapid pathogen detection, reliable testing, and improved patient management.

Logos and trademarks shown above are the property of their respective owners. Their use here is for informational and illustrative purposes only.

MARKET ECOSYSTEM

In the transplant diagnostics market, various stakeholders—including manufacturers, diagnostic laboratories, hospitals, transplant centers, and healthcare providers—collaborate to ensure efficient compatibility testing between donors and recipients, as well as smooth transplantation procedures. Manufacturers develop and supply molecular diagnostic technologies, such as PCR- and sequencing-based assays, which are used for applications like histocompatibility testing, infectious disease testing, and blood profiling. Laboratory personnel and transplant specialists depend on these technologies to conduct accurate and efficient transplant diagnostic procedures. The market is experiencing growth due to technological advancements, ongoing research activities, regulatory support, and partnerships among industry participants.

global-transplant-diagnostics-market Ecosystem

Logos and trademarks shown above are the property of their respective owners. Their use here is for informational and illustrative purposes only.

MARKET SEGMENTS

global-transplant-diagnostics-market Segments

Source: Secondary Research, Interviews with Experts, MarketsandMarkets Analysis

Transplant Diagnostics Market, by Product & Service

Based on product & service, the transplant diagnostics market is segmented into reagents & consumables, instruments, and software & services. In 2025, the reagents & consumables segment accounted for the largest share of the transplant diagnostics market. The dominance of this segment is mainly attributed to the growing focus on effective and early patient profiling during organ transplantation procedures, increasing adoption of transplant diagnostic techniques in research applications, and the rising number of organ transplantation procedures across major healthcare markets. Furthermore, the extensive use of reagents and consumables in molecular diagnostic techniques such as PCR- and sequencing-based testing for donor-recipient compatibility assessment, histocompatibility testing, and infectious disease testing is further contributing to the growth of this segment.

Transplant Diagnostics Market, by Technology

Based on technology, the transplant diagnostics market is segmented into molecular assays and non-molecular assays. The molecular assay technologies segment is further divided into PCR-based molecular assays and sequencing-based molecular assays. In 2025, the molecular assay technologies segment dominated the transplant diagnostics market. The growth of this segment is primarily attributed to the advantages offered by molecular assays, such as low turnaround time, high procedural efficiency, real-time sample analysis, and the ability to analyze multiple samples simultaneously. In addition, increasing applications in patient profiling, rising public-private investments for product development, growing clinical evidence supporting molecular assay techniques, and technological advancements are further supporting segment growth.

Transplant Diagnostics Market, by Application

Based on application, the transplant diagnostics market is segmented into diagnostic applications and research applications. In 2025, the diagnostic applications segment is expected to witness the fastest growth in the transplant diagnostics market. The growth of this segment is mainly attributed to technological advancements in molecular assay techniques and the increasing adoption of molecular assays for pathogen detection and histocompatibility testing. In addition, the rising prevalence of chronic diseases requiring transplantation and the growing risk of post-transplant infections and genetic disorders are further supporting the demand for transplant diagnostic procedures.

Transplant Diagnostics Market, by Type

Based on type, the transplant diagnostics market is segmented into solid organ transplantation, stem cell transplantation, soft tissue transplantation, and bone marrow transplantation. In 2025, the solid organ transplantation segment accounted for the largest share of the transplant diagnostics market. The dominance of this segment is mainly attributed to the increasing demand for donor-recipient compatibility testing, infectious disease testing, histocompatibility testing, genomic profiling, and blood profiling during solid organ transplantation procedures. In addition, the rising number of organ transplantation procedures, supportive government initiatives, increasing prevalence of chronic diseases requiring transplantation, and technological advancements in transplant diagnostics are further supporting the growth of this segment.

Transplant Diagnostics Market, by End User

Based on end user, the transplant diagnostics market is segmented into hospitals & transplant centers, research laboratories & academic institutes, and independent reference laboratories. In 2025, the independent reference laboratories segment dominated the transplant diagnostics market. The growth of this segment is mainly attributed to the increasing modernization and automation of diagnostic laboratories, rising outsourcing of research activities by pharmaceutical and biotechnology companies, and growing demand for infectious disease diagnosis and tissue typing during donor-recipient profiling and cross-matching procedures.

REGION

North America accounted for largest share of global transplant diagnostics market during forecast period.

In North America, several factors have influenced the growth of the transplant diagnostics market. These include the availability of advanced transplant diagnostic technologies, well-developed healthcare infrastructure, and increasing adoption of molecular diagnostic techniques. Other factors include growing public-private investments in transplant diagnostic research, government initiatives supporting genome-based medical diagnosis, and the presence of major industry participants. Rising demand for donor-recipient compatibility testing, increasing awareness regarding transplantation procedures, and the growing need for accurate diagnostic testing are some of the other factors supporting market growth in the region.

global-transplant-diagnostics-market Region

TRANSPLANT DIAGNOSTICS MARKET: COMPANY EVALUATION MATRIX

Thermo Fisher Scientific Inc. (US) is one of the key participants in the transplant diagnostics market with a diverse portfolio of molecular diagnostic technologies and transplant testing solutions. The company offers PCR- and sequencing-based technologies for donor-recipient compatibility testing, histocompatibility testing, infectious disease testing, and blood profiling during transplantation procedures. Geographically, Thermo Fisher Scientific has a strong presence across North America, Europe, and Asia Pacific, where it provides transplant diagnostic solutions to hospitals, transplant centers, diagnostic laboratories, and research institutes. The company focuses on technological advancements and continuous product development to improve the efficiency, accuracy, and reliability of transplant diagnostic procedures. In addition, its strong global distribution network and strategic collaborations further support its position in the transplant diagnostics market.

global-transplant-diagnostics-market Evaluation Metrics

Source: Secondary Research, Interviews with Experts, MarketsandMarkets Analysis

KEY MARKET PLAYERS

MARKET SCOPE

REPORT METRIC DETAILS
Market Size in 2025 (Value) USD 5.25 Billion
Market Forecast in 2026 (Value) USD 5.61 Billion
Market Forecast in 2031 (Value) USD 8.14 Billion
CAGR CAGR of 7.8% from 2026-2031
Years Considered 2024-2031
Base Year 2025
Forecast Period 2026-2031
Units Considered Value (USD Million/Billion)
Report Coverage Revenue Forecast, Company Ranking, Competitive Landscape, Growth Factors, and Trends
Segments Covered
  • By Product & Service:
    • Reagents & Consumables
    • Instruments
    • Software & Services
  • By Technology:
    • Molecular Assays
    • Non-molecular Assays
  • By Application:
    • Diagnostic Applications
    • Research Applications
  • By Transplant Type:
    • Solid Organ Transplantation
    • Stem Cell Transplantation
    • Soft Tissue Transplantation
    • Bone Marrow Transplantation
  • By End User:
    • Hospitals & Transplant Centers
    • Research & Academic Institutes
    • Independent Reference Laboratories
Regions Covered North America, Europe, Asia Pacific, Latin America, the Middle East & Africa

WHAT IS IN IT FOR YOU: TRANSPLANT DIAGNOSTICS MARKET REPORT CONTENT GUIDE

global-transplant-diagnostics-market Content Guide

DELIVERED CUSTOMIZATIONS

We have successfully delivered the following deep-dive customizations:

CLIENT REQUEST CUSTOMIZATION DELIVERED VALUE ADDS
Product Analysis ?  Product matrix, which provides a detailed comparison of the product portfolio of each company in the transplant diagnostics market Enables easy comparison of competitors’ offerings, helping identify gaps, overlaps, and differentiation opportunities.
Company Information ?  Additional five company profiles of players operating in the transplant diagnostics market. Provides insights into competitors’ strategies, innovation focus, and partnerships, supporting strategic planning.

RECENT DEVELOPMENTS

  • October 2024 : QIAGEN N.V. (Netherlands) expanded its automated liquid biopsy portfolio to support oncology, prenatal care, and organ transplant applications. The portfolio expansion was aimed at improving automated workflows and molecular diagnostic procedures used in organ transplantation.
  • October 2024 : Werfen (Spain) completed the acquisition of Omixon (Hungary), a company focused on next-generation sequencing (NGS)-based transplant diagnostic technologies. Through this acquisition, Werfen expanded its transplant diagnostics portfolio for hospitals and clinical laboratories.
  • March 2026 : F. Hoffmann-La Roche Ltd. (Switzerland) launched the cobas MPX-E assay, a 4-in-1 donor screening test designed to detect HIV, HCV, HBV, and HEV in a single test. The assay is intended to improve laboratory efficiency, reduce turnaround time, and support high-throughput donor screening workflows.

Table of Contents

Exclusive indicates content/data unique to MarketsandMarkets and not available with any competitors.

TITLE
PAGE NO
1
INTRODUCTION
 
 
 
 
 
41
2
EXECUTIVE SUMMARY
 
 
 
 
 
46
3
PREMIUM INSIGHTS
 
 
 
 
 
51
4
MARKET OVERVIEW
Surging transplant procedures and funding drive market growth amid cost and infrastructure challenges.
 
 
 
 
 
55
 
4.1
INTRODUCTION
 
 
 
 
 
 
4.2
MARKET DYNAMICS
 
 
 
 
 
 
 
4.2.1
DRIVERS
 
 
 
 
 
 
 
4.2.1.1
INCREASING NUMBER OF TRANSPLANT PROCEDURES
 
 
 
 
 
 
4.2.1.2
ADVANCEMENTS IN MOLECULAR DIAGNOSTIC TECHNOLOGIES
 
 
 
 
 
 
4.2.1.3
INCREASING PUBLIC-PRIVATE FUNDING FOR TRANSPLANT RESEARCH
 
 
 
 
 
 
4.2.1.4
RISING INCIDENCE OF CHRONIC DISEASES
 
 
 
 
 
4.2.2
RESTRAINTS
 
 
 
 
 
 
 
4.2.2.1
HIGH COST OF INSTRUMENTS AND CONSUMABLES
 
 
 
 
 
 
4.2.2.2
LIMITED ACCESS TO ADVANCED TRANSPLANT DIAGNOSTIC INFRASTRUCTURE IN EMERGING ECONOMIES
 
 
 
 
 
4.2.3
OPPORTUNITIES
 
 
 
 
 
 
 
4.2.3.1
INCREASING ADOPTION OF CROSS-MATCHING AND CHIMERISM TESTING
 
 
 
 
 
 
4.2.3.2
GROWING AWARENESS REGARDING ORGAN DONATION AND TRANSPLANTATION
 
 
 
 
 
4.2.4
CHALLENGES
 
 
 
 
 
 
 
4.2.4.1
GAP BETWEEN ORGAN DONOR AVAILABILITY AND TRANSPLANT DEMAND
 
 
 
 
4.3
UNMET NEEDS & WHITE SPACES
 
 
 
 
 
 
 
4.3.1
UNMET NEEDS IN TRANSPLANT DIAGNOSTICS MARKET
 
 
 
 
 
 
4.3.2
WHITE SPACE OPPORTUNITIES
 
 
 
 
 
4.4
INTERCONNECTED MARKETS & CROSS-SECTOR OPPORTUNITIES
 
 
 
 
 
 
 
4.4.1
INTERCONNECTED MARKETS
 
 
 
 
 
 
4.4.2
CROSS-SECTOR OPPORTUNITIES
 
 
 
 
 
4.5
STRATEGIC MOVES BY TIER 1/2/3 PLAYERS
 
 
 
 
 
 
 
4.5.1
KEY MOVES & STRATEGIC FOCUS
 
 
 
 
5
INDUSTRY TRENDS
Navigate industry shifts with comprehensive insights into competitive forces and pricing dynamics.
 
 
 
 
 
68
 
5.1
PORTER’S FIVE FORCES ANALYSIS
 
 
 
 
 
 
 
5.1.1
BARGAINING POWER OF SUPPLIERS
 
 
 
 
 
 
5.1.2
BARGAINING POWER OF BUYERS
 
 
 
 
 
 
5.1.3
THREAT OF NEW ENTRANTS
 
 
 
 
 
 
5.1.4
THREAT OF SUBSTITUTES
 
 
 
 
 
 
5.1.5
INTENSITY OF COMPETITIVE RIVALRY
 
 
 
 
 
5.2
MACROECONOMIC INDICATORS
 
 
 
 
 
 
 
5.2.1
INTRODUCTION
 
 
 
 
 
 
5.2.2
GDP TRENDS & FORECAST
 
 
 
 
 
5.3
SUPPLY CHAIN ANALYSIS
 
 
 
 
 
 
 
5.4
VALUE CHAIN ANALYSIS
 
 
 
 
 
 
 
5.5
ECOSYSTEM ANALYSIS
 
 
 
 
 
 
 
5.6
PRICING ANALYSIS
 
 
 
 
 
 
 
 
5.6.1
AVERAGE SELLING PRICE TREND OF TRANSPLANT DIAGNOSTIC PRODUCTS, BY KEY PLAYER, 2024–2026
 
 
 
 
 
 
5.6.2
AVERAGE SELLING PRICE TREND OF TRANSPLANT DIAGNOSTIC PRODUCTS, BY REGION, 2024–2026
 
 
 
 
 
5.7
TRADE ANALYSIS
 
 
 
 
 
 
 
 
5.7.1
IMPORT SCENARIO (HS CODE 3822)
 
 
 
 
 
 
5.7.2
EXPORT SCENARIO (HS CODE 3822)
 
 
 
 
 
5.8
KEY CONFERENCES & EVENTS, 2026–2027
 
 
 
 
 
 
5.9
TRENDS/DISRUPTIONS IMPACTING CUSTOMERS’ BUSINESSES
 
 
 
 
 
 
5.10
INVESTMENT & FUNDING SCENARIO
 
 
 
 
 
 
 
5.11
IMPACT OF 2025 US TARIFFS ON TRANSPLANT DIAGNOSTICS MARKET
 
 
 
 
 
 
 
 
5.11.1
INTRODUCTION
 
 
 
 
 
 
5.11.2
KEY TARIFF RATES
 
 
 
 
 
 
5.11.3
PRICE IMPACT ANALYSIS
 
 
 
 
 
 
5.11.4
IMPACT ON REGION
 
 
 
 
 
 
 
5.11.4.1
NORTH AMERICA
 
 
 
 
 
 
5.11.4.2
EUROPE
 
 
 
 
 
 
5.11.4.3
ASIA PACIFIC
 
 
 
 
 
5.11.5
IMPACT ON END-USE INDUSTRIES
 
 
 
 
 
 
 
5.11.5.1
HOSPITALS & TRANSPLANT CENTERS
 
 
 
 
 
 
5.11.5.2
RESEARCH & ACADEMIC INSTITUTES
 
 
 
 
 
 
5.11.5.3
INDEPENDENT REFERENCE LABORATORIES
 
 
 
6
TECHNOLOGICAL ADVANCEMENTS, AI-DRIVEN IMPACT, PATENTS, INNOVATIONS, AND FUTURE APPLICATIONS
AI-driven innovations redefine transplant diagnostics, unlocking market potential and future applications.
 
 
 
 
 
89
 
6.1
KEY EMERGING TECHNOLOGIES
 
 
 
 
 
 
 
6.1.1
DONOR-DERIVED CELL-FREE DNA (DD-CFDNA)
 
 
 
 
 
 
6.1.2
DIGITAL PCR (DPCR)
 
 
 
 
 
6.2
COMPLEMENTARY TECHNOLOGIES
 
 
 
 
 
 
 
6.2.1
AI IN TRANSPLANT DIAGNOSTICS
 
 
 
 
 
 
6.2.2
BIOINFORMATICS
 
 
 
 
 
6.3
ADJACENT TECHNOLOGIES
 
 
 
 
 
 
 
6.3.1
LIQUID BIOPSY
 
 
 
 
 
 
6.3.2
DIGITAL PATHOLOGY
 
 
 
 
 
6.4
TECHNOLOGY/PRODUCT ROADMAP
 
 
 
 
 
 
6.5
PATENT ANALYSIS
 
 
 
 
 
 
 
 
6.5.1
LIST OF KEY PATENTS
 
 
 
 
 
6.6
FUTURE APPLICATIONS
 
 
 
 
 
 
6.7
IMPACT OF AI/GENERATIVE AI ON TRANSPLANT DIAGNOSTICS MARKET
 
 
 
 
 
 
 
 
6.7.1
INTRODUCTION
 
 
 
 
 
 
6.7.2
TOP USE CASES & MARKET POTENTIAL
 
 
 
 
 
 
6.7.3
KEY COMPANIES IMPLEMENTING AI
 
 
 
 
 
 
6.7.4
FUTURE OF AI
 
 
 
 
7
SUSTAINABILITY & REGULATORY LANDSCAPE
Navigate complex sustainability regulations to enhance eco-friendly practices in transplant diagnostics globally.
 
 
 
 
 
100
 
7.1
REGIONAL REGULATIONS & COMPLIANCE
 
 
 
 
 
 
 
7.1.1
REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
 
 
 
 
 
7.2
SUSTAINABILITY INITIATIVES
 
 
 
 
 
 
 
7.2.1
ENVIRONMENTAL IMPACT & ECO-FRIENDLY INITIATIVES IN TRANSPLANT DIAGNOSTICS
 
 
 
 
 
 
 
7.2.1.1
ECO-FRIENDLY INITIATIVES
 
 
 
 
7.3
SUSTAINABILITY IMPACT & REGULATORY POLICY INITIATIVES
 
 
 
 
 
8
CUSTOMER LANDSCAPE & BUYER BEHAVIOR
Unlock untapped revenue by understanding stakeholder influence and unmet needs in buyer decisions.
 
 
 
 
 
105
 
8.1
DECISION-MAKING PROCESS
 
 
 
 
 
 
8.2
BUYER STAKEHOLDERS & BUYING EVALUATION CRITERIA
 
 
 
 
 
 
 
8.2.1
KEY STAKEHOLDERS IN BUYING PROCESS
 
 
 
 
 
 
8.2.2
BUYING CRITERIA
 
 
 
 
 
8.3
ADOPTION BARRIERS & INTERNAL CHALLENGES
 
 
 
 
 
 
8.4
UNMET NEEDS IN VARIOUS END-USE INDUSTRIES
 
 
 
 
 
 
8.5
MARKET PROFITABILITY
 
 
 
 
 
 
 
8.5.1
REVENUE POTENTIAL
 
 
 
 
 
 
8.5.2
COST DYNAMICS
 
 
 
 
 
 
8.5.3
MARGIN OPPORTUNITIES IN KEY APPLICATIONS
 
 
 
 
9
TRANSPLANT DIAGNOSTICS MARKET, BY PRODUCTS & SERVICES
Market Size & Growth Rate Forecast Analysis to 2031 in USD Million | 19 Data Tables
 
 
 
 
 
112
 
9.1
INTRODUCTION
 
 
 
 
 
 
9.2
REAGENTS & CONSUMABLES
 
 
 
 
 
 
 
9.2.1
REAGENTS & CONSUMABLES TO BE LARGEST AND FASTEST-GROWING SEGMENT IN TRANSPLANT DIAGNOSTICS MARKET
 
 
 
 
 
9.3
INSTRUMENTS
 
 
 
 
 
 
 
9.3.1
INCREASING PUBLIC-PRIVATE INVESTMENTS TO DRIVE MARKET
 
 
 
 
 
9.4
SOFTWARE & SERVICES
 
 
 
 
 
 
 
9.4.1
GROWING AUTOMATION & DIGITALIZATION OF DIAGNOSTIC LABORATORY PROCEDURES TO SUPPORT MARKET GROWTH
 
 
 
 
10
TRANSPLANT DIAGNOSTICS MARKET, BY TECHNOLOGY
Market Size & Growth Rate Forecast Analysis to 2031 in USD Million | 70 Data Tables
 
 
 
 
 
123
 
10.1
INTRODUCTION
 
 
 
 
 
 
10.2
MOLECULAR ASSAYS
 
 
 
 
 
 
 
10.2.1
PCR-BASED MOLECULAR ASSAYS
 
 
 
 
 
 
 
10.2.1.1
REAL-TIME PCR
 
 
 
 
 
 
 
 
10.2.1.1.1
SMALLER SAMPLE VOLUME REQUIREMENTS COMPARED TO CONVENTIONAL PCR TECHNOLOGIES TO DRIVE DEMAND
 
 
 
 
10.2.1.2
SEQUENCE-SPECIFIC PRIMER-PCR (SSP-PCR)
 
 
 
 
 
 
 
 
10.2.1.2.1
GROWING PUBLIC-PRIVATE INVESTMENTS FOR RESEARCH ACTIVITIES TO SUPPORT MARKET GROWTH
 
 
 
 
10.2.1.3
SEQUENCE-SPECIFIC OLIGONUCLEOTIDE-PCR (SSO-PCR)
 
 
 
 
 
 
 
 
10.2.1.3.1
WIDE ADOPTION OF TECHNIQUE IN PCR-BASED MOLECULAR ASSAYS MARKET TO FUEL GROWTH
 
 
 
 
10.2.1.4
OTHER PCR-BASED MOLECULAR ASSAYS
 
 
 
 
 
10.2.2
SEQUENCING-BASED MOLECULAR ASSAYS
 
 
 
 
 
 
 
10.2.2.1
SANGER SEQUENCING
 
 
 
 
 
 
 
 
10.2.2.1.1
GROWING DEMAND FOR HIGH-THROUGHPUT DNA SEQUENCERS IN TRANSPLANT DIAGNOSTIC APPLICATIONS TO DRIVE MARKET
 
 
 
 
10.2.2.2
NEXT-GENERATION SEQUENCING (NGS)
 
 
 
 
 
 
 
 
10.2.2.2.1
LOW TURNAROUND TIME AND HIGH-THROUGHPUT SEQUENCING TO DRIVE ADOPTION OF NGS
 
 
 
 
10.2.2.3
OTHER SEQUENCING-BASED MOLECULAR ASSAYS
 
 
 
 
10.3
NON-MOLECULAR ASSAYS
 
 
 
 
 
 
 
10.3.1
REPLACEMENT OF NON-MOLECULAR ASSAY TECHNIQUES WITH DNA-BASED TECHNIQUES TO HAMPER GROWTH
 
 
 
 
11
TRANSPLANT DIAGNOSTICS MARKET, BY APPLICATION
Market Size & Growth Rate Forecast Analysis to 2031 in USD Million | 45 Data Tables
 
 
 
 
 
161
 
11.1
INTRODUCTION
 
 
 
 
 
 
11.2
DIAGNOSTIC APPLICATIONS
 
 
 
 
 
 
 
11.2.1
PRE-TRANSPLANTATION DIAGNOSTICS
 
 
 
 
 
 
 
11.2.1.1
INFECTIOUS DISEASE TESTING
 
 
 
 
 
 
 
 
11.2.1.1.1
GROWING ADOPTION OF ADVANCED MOLECULAR TECHNIQUES FOR PATHOGEN DETECTION TO DRIVE MARKET
 
 
 
 
11.2.1.2
HISTOCOMPATIBILITY TESTING
 
 
 
 
 
 
 
 
11.2.1.2.1
TECHNOLOGICAL ADVANCEMENTS AND GROWING R&D ACTIVITIES TO PROPEL MARKET
 
 
 
 
11.2.1.3
BLOOD PROFILING
 
 
 
 
 
 
 
 
11.2.1.3.1
GROWING AVAILABILITY OF MOLECULAR ASSAY PRODUCTS TO SUPPORT MARKET GROWTH
 
 
 
11.2.2
POST-TRANSPLANTATION DIAGNOSTICS
 
 
 
 
 
 
 
11.2.2.1
GREATER RISK OF DISORDERS AND INFECTIONS POST-TRANSPLANTATION TO MAKE DIAGNOSTICS NECESSARY STEP
 
 
 
 
11.3
RESEARCH APPLICATIONS
 
 
 
 
 
 
 
11.3.1
GROWING FUNDING FOR RESEARCH TO DRIVE MARKET
 
 
 
 
12
TRANSPLANT DIAGNOSTICS MARKET, BY TYPE
Market Size & Growth Rate Forecast Analysis to 2031 in USD Million | 62 Data Tables
 
 
 
 
 
185
 
12.1
INTRODUCTION
 
 
 
 
 
 
12.2
SOLID ORGAN TRANSPLANTATION
 
 
 
 
 
 
 
12.2.1
KIDNEY TRANSPLANTATION
 
 
 
 
 
 
 
12.2.1.1
RISING PREVALENCE OF KIDNEY DISEASES TO DRIVE MARKET
 
 
 
 
 
12.2.2
LIVER TRANSPLANTATION
 
 
 
 
 
 
 
12.2.2.1
GROWING PATIENT POPULATION WITH CHRONIC LIVER DISEASES AND INCREASING PROCEDURAL VOLUME TO DRIVE MARKET
 
 
 
 
 
12.2.3
LUNG TRANSPLANTATION
 
 
 
 
 
 
 
12.2.3.1
RISING PREVALENCE OF CHRONIC LUNG DISEASES TO DRIVE MARKET
 
 
 
 
 
12.2.4
HEART TRANSPLANTATION
 
 
 
 
 
 
 
12.2.4.1
INCREASING PREVALENCE OF CHRONIC CARDIAC DISEASES TO PROPEL MARKET
 
 
 
 
 
12.2.5
PANCREAS TRANSPLANTATION
 
 
 
 
 
 
 
12.2.5.1
PROCEDURAL COMPLEXITY AND RISK OF SURGICAL COMPLICATIONS TO RESTRAIN GROWTH
 
 
 
 
 
12.2.6
OTHER SOLID ORGAN TRANSPLANTATION
 
 
 
 
 
12.3
STEM CELL TRANSPLANTATION
 
 
 
 
 
 
 
12.3.1
RISING PROCEDURAL VOLUME AND GROWING RESEARCH ACTIVITIES TO DRIVE MARKET
 
 
 
 
 
12.4
SOFT TISSUE TRANSPLANTATION
 
 
 
 
 
 
 
12.4.1
TECHNOLOGICAL ADVANCEMENTS AND RISING PREVALENCE OF TARGET DISEASES TO DRIVE MARKET
 
 
 
 
 
12.5
BONE MARROW TRANSPLANTATION
 
 
 
 
 
 
 
12.5.1
DEARTH OF WELL-TRAINED SURGEONS TO PERFORM BONE MARROW TRANSPLANTATION TO HINDER GROWTH
 
 
 
 
13
TRANSPLANT DIAGNOSTICS MARKET, BY END USER
Market Size & Growth Rate Forecast Analysis to 2031 in USD Million | 19 Data Tables
 
 
 
 
 
218
 
13.1
INTRODUCTION
 
 
 
 
 
 
13.2
INDEPENDENT REFERENCE LABORATORIES
 
 
 
 
 
 
 
13.2.1
RISING CONSOLIDATION OF DIAGNOSTIC LABORATORIES TO DRIVE MARKET
 
 
 
 
 
13.3
HOSPITALS & TRANSPLANT CENTERS
 
 
 
 
 
 
 
13.3.1
GROWING PURCHASING POWER OF HOSPITALS & TRANSPLANT CENTERS TO SUPPORT MARKET GROWTH
 
 
 
 
 
13.4
RESEARCH LABORATORIES & ACADEMIC INSTITUTES
 
 
 
 
 
 
 
13.4.1
INCREASING INDUSTRY-ACADEMIA COLLABORATIONS IN GENOMICS-BASED TRANSPLANT DIAGNOSTIC RESEARCH TO DRIVE MARKET
 
 
 
 
14
TRANSPLANT DIAGNOSTICS MARKET, BY REGION
Comprehensive coverage of 7 Regions with country-level deep-dive of 16 Countries | 287 Data Tables.
 
 
 
 
 
230
 
14.1
INTRODUCTION
 
 
 
 
 
 
14.2
NORTH AMERICA
 
 
 
 
 
 
 
14.2.1
US
 
 
 
 
 
 
 
14.2.1.1
GROWING ORGAN TRANSPLANTATION ACTIVITY TO SUPPORT MARKET EXPANSION
 
 
 
 
 
14.2.2
CANADA
 
 
 
 
 
 
 
14.2.2.1
GROWING TRANSPLANT PROGRAMS TO SUPPORT MARKET GROWTH
 
 
 
 
14.3
EUROPE
 
 
 
 
 
 
 
14.3.1
GERMANY
 
 
 
 
 
 
 
14.3.1.1
EXPANDING DONOR REGISTRY NETWORK TO FUEL MARKET GROWTH
 
 
 
 
 
14.3.2
UK
 
 
 
 
 
 
 
14.3.2.1
RISING TRANSPLANT DEMAND TO SUPPORT MARKET GROWTH
 
 
 
 
 
14.3.3
FRANCE
 
 
 
 
 
 
 
14.3.3.1
GROWING ORGAN DONATION INITIATIVES TO DRIVE GROWTH
 
 
 
 
 
14.3.4
ITALY
 
 
 
 
 
 
 
14.3.4.1
INCREASING ORGAN DONATION RATES TO DRIVE MARKET GROWTH
 
 
 
 
 
14.3.5
SPAIN
 
 
 
 
 
 
 
14.3.5.1
STRONG ORGAN DONATION SYSTEM TO SUPPORT MARKET GROWTH
 
 
 
 
 
14.3.6
REST OF EUROPE
 
 
 
 
 
14.4
ASIA PACIFIC
 
 
 
 
 
 
 
14.4.1
CHINA
 
 
 
 
 
 
 
14.4.1.1
EXPANDING TRANSPLANTATION PROGRAMS TO DRIVE MARKET GROWTH
 
 
 
 
 
14.4.2
JAPAN
 
 
 
 
 
 
 
14.4.2.1
GROWING TRANSPLANT WAITING POPULATION TO SUPPORT MARKET GROWTH
 
 
 
 
 
14.4.3
INDIA
 
 
 
 
 
 
 
14.4.3.1
RISING TRANSPLANT PROCEDURES TO DRIVE MARKET GROWTH
 
 
 
 
 
14.4.4
AUSTRALIA
 
 
 
 
 
 
 
14.4.4.1
RISING NUMBER OF SOLID ORGAN TRANSPLANTATION PROCEDURES TO DRIVE MARKET
 
 
 
 
 
14.4.5
SOUTH KOREA
 
 
 
 
 
 
 
14.4.5.1
LARGE TRANSPLANT WAITING POPULATION TO DRIVE MARKET GROWTH
 
 
 
 
 
14.4.6
REST OF ASIA PACIFIC
 
 
 
 
 
14.5
LATIN AMERICA
 
 
 
 
 
 
 
14.5.1
BRAZIL
 
 
 
 
 
 
 
14.5.1.1
EXPANDING TRANSPLANT PROGRAMS TO DRIVE MARKET GROWTH
 
 
 
 
 
14.5.2
MEXICO
 
 
 
 
 
 
 
14.5.2.1
GROWING MEDICAL TOURISM TO SUPPORT MARKET GROWTH
 
 
 
 
 
14.5.3
REST OF LATIN AMERICA
 
 
 
 
 
14.6
MIDDLE EAST & AFRICA
 
 
 
 
 
 
 
14.6.1
UAE
 
 
 
 
 
 
 
14.6.1.1
EXPANDING ORGAN DONATION PROGRAMS TO DRIVE MARKET GROWTH
 
 
 
 
 
14.6.2
SAUDI ARABIA
 
 
 
 
 
 
 
14.6.2.1
STRENGTHENING TRANSPLANTATION CAPABILITIES TO SUPPORT MARKET GROWTH
 
 
 
 
 
14.6.3
REST OF MIDDLE EAST & AFRICA
 
 
 
 
 
 
14.6.4
US: HEART, LIVER, AND LUNG TRANSPLANTS MARKET VOLUME
 
 
 
 
15
COMPETITIVE LANDSCAPE
Uncover key player strategies and market share dynamics shaping transplant diagnostics' competitive edge.
 
 
 
 
 
364
 
15.1
INTRODUCTION
 
 
 
 
 
 
15.2
KEY PLAYER STRATEGIES/RIGHT TO WIN
 
 
 
 
 
 
 
15.2.1
OVERVIEW OF STRATEGIES DEPLOYED BY PLAYERS IN TRANSPLANT DIAGNOSTICS MARKET
 
 
 
 
 
15.3
REVENUE ANALYSIS, 2023–2025
 
 
 
 
 
 
 
15.4
MARKET SHARE ANALYSIS, 2025
 
 
 
 
 
 
 
 
15.4.1
GLOBAL MARKET SHARE ANALYSIS, 2025
 
 
 
 
 
15.5
COMPANY EVALUATION MATRIX: KEY PLAYERS, 2025
 
 
 
 
 
 
 
 
15.5.1
STARS
 
 
 
 
 
 
15.5.2
EMERGING LEADERS
 
 
 
 
 
 
15.5.3
PERVASIVE PLAYERS
 
 
 
 
 
 
15.5.4
PARTICIPANTS
 
 
 
 
 
 
15.5.5
COMPANY FOOTPRINT: KEY PLAYERS, 2025
 
 
 
 
 
 
 
15.5.5.1
COMPANY FOOTPRINT
 
 
 
 
 
 
15.5.5.2
REGION FOOTPRINT
 
 
 
 
 
 
15.5.5.3
PRODUCT & SERVICE FOOTPRINT
 
 
 
 
 
 
15.5.5.4
APPLICATION FOOTPRINT
 
 
 
 
 
 
15.5.5.5
END-USER FOOTPRINT
 
 
 
 
15.6
COMPANY EVALUATION MATRIX: STARTUPS/SMES, 2025
 
 
 
 
 
 
 
 
15.6.1
PROGRESSIVE COMPANIES
 
 
 
 
 
 
15.6.2
RESPONSIVE COMPANIES
 
 
 
 
 
 
15.6.3
DYNAMIC COMPANIES
 
 
 
 
 
 
15.6.4
STARTING BLOCKS
 
 
 
 
 
 
15.6.5
COMPANY EVALUATION MATRIX: STARTUPS/SMES, 2025
 
 
 
 
 
 
 
15.6.5.1
DETAILED LIST OF KEY STARTUPS/SMES
 
 
 
 
 
 
15.6.5.2
COMPETITIVE BENCHMARKING OF STARTUPS/SMES (1/2)
 
 
 
 
 
 
15.6.5.3
COMPETITIVE BENCHMARKING OF STARTUPS/SMES (2/2)
 
 
 
 
15.7
COMPANY VALUATION & FINANCIAL METRICS
 
 
 
 
 
 
 
15.7.1
FINANCIAL METRICS
 
 
 
 
 
 
15.7.2
COMPANY VALUATION
 
 
 
 
 
15.8
BRAND/PRODUCT COMPARISON
 
 
 
 
 
 
 
15.9
COMPETITIVE SCENARIO
 
 
 
 
 
 
 
15.9.1
PRODUCT/SERVICE LAUNCHES & APPROVALS
 
 
 
 
 
 
15.9.2
DEALS
 
 
 
 
 
 
15.9.3
EXPANSIONS
 
 
 
 
16
COMPANY PROFILES
In-depth Company Profiles of Leading Market Players with detailed Business Overview, Product and Service Portfolio, Recent Developments, and Unique Analyst Perspective (MnM View)
 
 
 
 
 
386
 
16.1
KEY PLAYERS
 
 
 
 
 
 
 
16.1.1
THERMO FISHER SCIENTIFIC INC.
 
 
 
 
 
 
 
16.1.1.1
BUSINESS OVERVIEW
 
 
 
 
 
 
16.1.1.2
PRODUCTS OFFERED
 
 
 
 
 
 
16.1.1.3
RECENT DEVELOPMENTS
 
 
 
 
 
 
 
 
16.1.1.3.1
PRODUCT & SERVICE LAUNCHES
 
 
 
 
 
 
16.1.1.3.2
DEALS
 
 
 
 
 
 
16.1.1.3.3
EXPANSIONS
 
 
 
 
16.1.1.4
MNM VIEW
 
 
 
 
 
 
 
 
16.1.1.4.1
RIGHT TO WIN
 
 
 
 
 
 
16.1.1.4.2
STRATEGIC CHOICES
 
 
 
 
 
 
16.1.1.4.3
WEAKNESSES & COMPETITIVE THREATS
 
 
 
16.1.2
F. HOFFMANN-LA ROCHE LTD.
 
 
 
 
 
 
16.1.3
BIO-RAD LABORATORIES, INC.
 
 
 
 
 
 
16.1.4
QIAGEN N.V.
 
 
 
 
 
 
16.1.5
BIOMÉRIEUX
 
 
 
 
 
 
16.1.6
ILLUMINA, INC.
 
 
 
 
 
 
16.1.7
BECTON, DICKINSON AND COMPANY
 
 
 
 
 
 
16.1.8
CAREDX, INC.
 
 
 
 
 
 
16.1.9
DIASORIN S.P.A.
 
 
 
 
 
 
16.1.10
WERFEN
 
 
 
 
 
 
16.1.11
MERCK KGAA
 
 
 
 
 
 
16.1.12
HOLOGIC, INC.
 
 
 
 
 
16.2
OTHER PLAYERS
 
 
 
 
 
 
 
16.2.1
EUROBIO SCIENTIFIC
 
 
 
 
 
 
16.2.2
BIOFORTUNA LIMITED
 
 
 
 
 
 
16.2.3
BAG DIAGNOSTICS GMBH
 
 
 
 
 
 
16.2.4
FUJIREBIO
 
 
 
 
 
 
16.2.5
HISTOGENETICS LLC
 
 
 
 
 
 
16.2.6
PACBIO
 
 
 
 
 
 
16.2.7
TBG BIOTECHNOLOGY CORP
 
 
 
 
 
 
16.2.8
SCISCO GENETICS, INC.
 
 
 
 
 
 
16.2.9
INNO-TRAIN DIAGNOSTIK GMBH
 
 
 
 
 
 
16.2.10
BIONOBIS
 
 
 
 
 
 
16.2.11
TAKARA BIO INC.
 
 
 
 
 
 
16.2.12
KRISHGEN BIOSYSTEMS PRIVATE LIMITED
 
 
 
 
 
 
16.2.13
PROIMMUNE LTD.
 
 
 
 
17
RESEARCH METHODOLOGY
 
 
 
 
 
453
 
17.1
RESEARCH DATA
 
 
 
 
 
 
 
17.1.1
SECONDARY DATA
 
 
 
 
 
 
 
17.1.1.1
LIST OF SECONDARY SOURCES
 
 
 
 
 
 
17.1.1.2
KEY DATA FROM SECONDARY SOURCES
 
 
 
 
 
17.1.2
PRIMARY DATA
 
 
 
 
 
 
 
17.1.2.1
LIST OF PRIMARY SOURCES
 
 
 
 
 
 
17.1.2.2
KEY DATA FROM PRIMARY SOURCES
 
 
 
 
 
 
17.1.2.3
KEY INDUSTRY INSIGHTS
 
 
 
 
 
 
17.1.2.4
BREAKDOWN OF PRIMARY INTERVIEWS
 
 
 
 
17.2
MARKET SIZE ESTIMATION
 
 
 
 
 
 
 
17.2.1
TOTAL MARKET SIZE: TRANSPLANT DIAGNOSTICS MARKET
 
 
 
 
 
 
17.2.2
BOTTOM-UP APPROACH
 
 
 
 
 
 
 
17.2.2.1
APPROACH 1: REVENUE ESTIMATION OF KEY PLAYERS
 
 
 
 
 
 
17.2.2.2
APPROACH 2: STUDY OF ANNUAL REPORTS AND INVESTOR PRESENTATIONS
 
 
 
 
 
 
17.2.2.3
APPROACH 3: PRIMARY INTERVIEWS
 
 
 
 
 
 
17.2.2.4
GROWTH FORECAST
 
 
 
 
 
 
17.2.2.5
CAGR PROJECTIONS
 
 
 
 
 
17.2.3
TOP-DOWN APPROACH
 
 
 
 
 
17.3
DATA TRIANGULATION
 
 
 
 
 
 
17.4
RESEARCH ASSUMPTIONS
 
 
 
 
 
 
 
17.4.1
STUDY-RELATED ASSUMPTIONS
 
 
 
 
 
17.5
STUDY ASSUMPTIONS
 
 
 
 
 
 
 
17.5.1
PARAMETRIC ASSUMPTIONS
 
 
 
 
 
 
17.5.2
GROWTH RATE ASSUMPTIONS
 
 
 
 
 
17.6
RESEARCH LIMITATIONS
 
 
 
 
 
 
17.7
RISK ASSESSMENT
 
 
 
 
 
18
APPENDIX
 
 
 
 
 
466
 
18.1
DISCUSSION GUIDE
 
 
 
 
 
 
18.2
KNOWLEDGESTORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL
 
 
 
 
 
 
18.3
CUSTOMIZATION OPTIONS
 
 
 
 
 
 
18.4
RELATED REPORTS
 
 
 
 
 
 
18.5
AUTHOR DETAILS
 
 
 
 
 
LIST OF TABLES
 
 
 
 
 
 
 
TABLE 1
TRANSPLANT DIAGNOSTICS MARKET: PORTER’S FIVE FORCES ANALYSIS
 
 
 
 
 
 
TABLE 2
GDP PERCENTAGE CHANGE (%), BY KEY COUNTRY, 2023–2030
 
 
 
 
 
 
TABLE 3
NORTH AMERICA: MACROECONOMIC INDICATORS
 
 
 
 
 
 
TABLE 4
EUROPE: MACROECONOMIC INDICATORS
 
 
 
 
 
 
TABLE 5
ASIA PACIFIC: MACROECONOMIC INDICATORS
 
 
 
 
 
 
TABLE 6
LATIN AMERICA: MACROECONOMIC INDICATORS
 
 
 
 
 
 
TABLE 7
MIDDLE EAST & AFRICA: MACROECONOMIC INDICATORS
 
 
 
 
 
 
TABLE 8
TRANSPLANT DIAGNOSTICS MARKET: ROLE OF COMPANIES IN ECOSYSTEM
 
 
 
 
 
 
TABLE 9
AVERAGE SELLING PRICE TREND OF TRANSPLANT DIAGNOSTIC PRODUCTS, BY KEY PLAYER, 2024–2026 (USD)
 
 
 
 
 
 
TABLE 10
AVERAGE SELLING PRICE TREND OF TRANSPLANT DIAGNOSTIC PRODUCTS, BY REGION, 2024–2026 (USD)
 
 
 
 
 
 
TABLE 11
IMPORT DATA FOR HS CODE 3822-COMPLIANT PRODUCTS, BY COUNTRY, 2021–2025 (USD MILLION)
 
 
 
 
 
 
TABLE 12
EXPORT DATA FOR HS CODE 3822-COMPLIANT PRODUCTS, BY COUNTRY, 2021–2025 (USD MILLION)
 
 
 
 
 
 
TABLE 13
TRANSPLANT DIAGNOSTICS MARKET: KEY CONFERENCES & EVENTS, 2026–2027
 
 
 
 
 
 
TABLE 14
US-ADJUSTED RECIPROCAL TARIFF RATES
 
 
 
 
 
 
TABLE 15
KEY PATENTS IN TRANSPLANT DIAGNOSTICS MARKET, 2022–2026
 
 
 
 
 
 
TABLE 16
KEY COMPANIES IMPLEMENTING AI IN TRANSPLANT DIAGNOSTICS MARKET
 
 
 
 
 
 
TABLE 17
NORTH AMERICA: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
 
 
 
 
 
 
TABLE 18
EUROPE: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
 
 
 
 
 
 
TABLE 19
ASIA PACIFIC: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
 
 
 
 
 
 
TABLE 20
LATIN AMERICA: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
 
 
 
 
 
 
TABLE 21
REST OF THE WORLD: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
 
 
 
 
 
 
TABLE 22
INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS, BY PRODUCT & SERVICE (%)
 
 
 
 
 
 
TABLE 23
KEY BUYING CRITERIA, BY PRODUCT & SERVICE
 
 
 
 
 
 
TABLE 24
ADOPTION BARRIERS & INTERNAL CHALLENGES
 
 
 
 
 
 
TABLE 25
TRANSPLANT DIAGNOSTICS MARKET: UNMET NEEDS IN VARIOUS END-USE INDUSTRIES
 
 
 
 
 
 
TABLE 26
TRANSPLANT DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 27
TRANSPLANT DIAGNOSTICS MARKET FOR REAGENTS & CONSUMABLES, BY REGION, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 28
NORTH AMERICA: TRANSPLANT DIAGNOSTICS MARKET FOR REAGENTS & CONSUMABLES, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 29
EUROPE: TRANSPLANT DIAGNOSTICS MARKET FOR REAGENTS & CONSUMABLES, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 30
ASIA PACIFIC: TRANSPLANT DIAGNOSTICS MARKET FOR REAGENTS & CONSUMABLES, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 31
LATIN AMERICA: TRANSPLANT DIAGNOSTICS MARKET FOR REAGENTS & CONSUMABLES, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 32
MIDDLE EAST & AFRICA: TRANSPLANT DIAGNOSTICS MARKET FOR REAGENTS & CONSUMABLES, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 33
TRANSPLANT DIAGNOSTICS MARKET FOR INSTRUMENTS, BY REGION, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 34
NORTH AMERICA: TRANSPLANT DIAGNOSTICS MARKET FOR INSTRUMENTS, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 35
EUROPE: TRANSPLANT DIAGNOSTICS MARKET FOR INSTRUMENTS, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 36
ASIA PACIFIC: TRANSPLANT DIAGNOSTICS MARKET FOR INSTRUMENTS, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 37
LATIN AMERICA: TRANSPLANT DIAGNOSTICS MARKET FOR INSTRUMENTS, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 38
MIDDLE EAST & AFRICA: TRANSPLANT DIAGNOSTICS MARKET FOR INSTRUMENTS, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 39
TRANSPLANT DIAGNOSTICS MARKET FOR SOFTWARE & SERVICES, BY REGION, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 40
NORTH AMERICA: TRANSPLANT DIAGNOSTICS MARKET FOR SOFTWARE & SERVICES, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 41
EUROPE: TRANSPLANT DIAGNOSTICS MARKET FOR SOFTWARE & SERVICES, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 42
ASIA PACIFIC: TRANSPLANT DIAGNOSTICS MARKET FOR SOFTWARE & SERVICES, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 43
LATIN AMERICA: TRANSPLANT DIAGNOSTICS MARKET FOR SOFTWARE & SERVICES, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 44
MIDDLE EAST & AFRICA: TRANSPLANT DIAGNOSTICS MARKET FOR SOFTWARE & SERVICES, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 45
TRANSPLANT DIAGNOSTICS MARKET, BY TECHNOLOGY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 46
TRANSPLANT DIAGNOSTICS MARKET FOR MOLECULAR ASSAYS, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 47
TRANSPLANT DIAGNOSTICS MARKET FOR MOLECULAR ASSAYS, BY REGION, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 48
NORTH AMERICA: TRANSPLANT DIAGNOSTICS MARKET FOR MOLECULAR ASSAYS, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 49
EUROPE: TRANSPLANT DIAGNOSTICS MARKET FOR MOLECULAR ASSAYS, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 50
ASIA PACIFIC: TRANSPLANT DIAGNOSTICS MARKET FOR MOLECULAR ASSAYS, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 51
LATIN AMERICA: TRANSPLANT DIAGNOSTICS MARKET FOR MOLECULAR ASSAYS, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 52
MIDDLE EAST & AFRICA: TRANSPLANT DIAGNOSTICS MARKET FOR MOLECULAR ASSAYS, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 53
TRANSPLANT DIAGNOSTICS MARKET FOR PCR-BASED MOLECULAR ASSAYS, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 54
TRANSPLANT DIAGNOSTICS MARKET FOR PCR-BASED MOLECULAR ASSAYS, BY REGION, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 55
NORTH AMERICA: TRANSPLANT DIAGNOSTICS MARKET FOR PCR-BASED MOLECULAR ASSAYS, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 56
EUROPE: TRANSPLANT DIAGNOSTICS MARKET FOR PCR-BASED MOLECULAR ASSAYS, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 57
ASIA PACIFIC: TRANSPLANT DIAGNOSTICS MARKET FOR PCR-BASED MOLECULAR ASSAYS, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 58
LATIN AMERICA: TRANSPLANT DIAGNOSTICS MARKET FOR PCR-BASED MOLECULAR ASSAYS, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 59
MIDDLE EAST & AFRICA: TRANSPLANT DIAGNOSTICS MARKET FOR PCR-BASED MOLECULAR ASSAYS, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 60
TRANSPLANT DIAGNOSTICS MARKET FOR REAL-TIME PCR, BY REGION, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 61
NORTH AMERICA: TRANSPLANT DIAGNOSTICS MARKET FOR REAL-TIME PCR, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 62
EUROPE: TRANSPLANT DIAGNOSTICS MARKET FOR REAL-TIME PCR, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 63
ASIA PACIFIC: TRANSPLANT DIAGNOSTICS MARKET FOR REAL-TIME PCR, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 64
LATIN AMERICA: TRANSPLANT DIAGNOSTICS MARKET FOR REAL-TIME PCR, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 65
MIDDLE EAST & AFRICA: TRANSPLANT DIAGNOSTICS MARKET FOR REAL-TIME PCR, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 66
TRANSPLANT DIAGNOSTICS MARKET FOR SEQUENCE-SPECIFIC PRIMER-PCR, BY REGION, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 67
NORTH AMERICA: TRANSPLANT DIAGNOSTICS MARKET FOR SEQUENCE-SPECIFIC PRIMER-PCR, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 68
EUROPE: TRANSPLANT DIAGNOSTICS MARKET FOR SEQUENCE-SPECIFIC PRIMER-PCR, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 69
ASIA PACIFIC: TRANSPLANT DIAGNOSTICS MARKET FOR SEQUENCE-SPECIFIC PRIMER-PCR, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 70
LATIN AMERICA: TRANSPLANT DIAGNOSTICS MARKET FOR SEQUENCE-SPECIFIC PRIMER-PCR, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 71
MIDDLE EAST & AFRICA: TRANSPLANT DIAGNOSTICS MARKET FOR SEQUENCE-SPECIFIC PRIMER-PCR, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 72
TRANSPLANT DIAGNOSTICS MARKET FOR SEQUENCE-SPECIFIC OLIGONUCLEOTIDE-PCR, BY REGION, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 73
NORTH AMERICA: TRANSPLANT DIAGNOSTICS MARKET FOR SEQUENCE-SPECIFIC OLIGONUCLEOTIDE-PCR, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 74
EUROPE: TRANSPLANT DIAGNOSTICS MARKET FOR SEQUENCE-SPECIFIC OLIGONUCLEOTIDE-PCR, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 75
ASIA PACIFIC: TRANSPLANT DIAGNOSTICS MARKET FOR SEQUENCE-SPECIFIC OLIGONUCLEOTIDE-PCR, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 76
LATIN AMERICA: TRANSPLANT DIAGNOSTICS MARKET FOR SEQUENCE-SPECIFIC OLIGONUCLEOTIDE-PCR, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 77
MIDDLE EAST & AFRICA: TRANSPLANT DIAGNOSTICS MARKET FOR SEQUENCE-SPECIFIC OLIGONUCLEOTIDE-PCR, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 78
TRANSPLANT DIAGNOSTICS MARKET FOR OTHER PCR-BASED MOLECULAR ASSAYS, BY REGION, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 79
NORTH AMERICA: TRANSPLANT DIAGNOSTICS MARKET FOR OTHER PCR-BASED MOLECULAR ASSAYS, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 80
EUROPE: TRANSPLANT DIAGNOSTICS MARKET FOR OTHER PCR-BASED MOLECULAR ASSAYS, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 81
ASIA PACIFIC: TRANSPLANT DIAGNOSTICS MARKET FOR OTHER PCR-BASED MOLECULAR ASSAYS, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 82
LATIN AMERICA: TRANSPLANT DIAGNOSTICS MARKET FOR OTHER PCR-BASED MOLECULAR ASSAYS, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 83
MIDDLE EAST & AFRICA: TRANSPLANT DIAGNOSTICS MARKET FOR OTHER PCR-BASED MOLECULAR ASSAYS, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 84
TRANSPLANT DIAGNOSTICS MARKET FOR SEQUENCING-BASED MOLECULAR ASSAYS, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 85
TRANSPLANT DIAGNOSTICS MARKET FOR SEQUENCING-BASED MOLECULAR ASSAYS, BY REGION, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 86
NORTH AMERICA: TRANSPLANT DIAGNOSTICS MARKET FOR SEQUENCING-BASED MOLECULAR ASSAYS, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 87
EUROPE: TRANSPLANT DIAGNOSTICS MARKET FOR SEQUENCING-BASED MOLECULAR ASSAYS, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 88
ASIA PACIFIC: TRANSPLANT DIAGNOSTICS MARKET FOR SEQUENCING-BASED MOLECULAR ASSAYS, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 89
LATIN AMERICA: TRANSPLANT DIAGNOSTICS MARKET FOR SEQUENCING-BASED MOLECULAR ASSAYS, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 90
MIDDLE EAST & AFRICA: TRANSPLANT DIAGNOSTICS MARKET FOR SEQUENCING-BASED MOLECULAR ASSAYS, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 91
TRANSPLANT DIAGNOSTICS MARKET FOR SANGER SEQUENCING, BY REGION, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 92
NORTH AMERICA: TRANSPLANT DIAGNOSTICS MARKET FOR SANGER SEQUENCING, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 93
EUROPE: TRANSPLANT DIAGNOSTICS MARKET FOR SANGER SEQUENCING, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 94
ASIA PACIFIC: TRANSPLANT DIAGNOSTICS MARKET FOR SANGER SEQUENCING, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 95
LATIN AMERICA: TRANSPLANT DIAGNOSTICS MARKET FOR SANGER SEQUENCING, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 96
MIDDLE EAST & AFRICA: TRANSPLANT DIAGNOSTICS MARKET FOR SANGER SEQUENCING, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 97
TRANSPLANT DIAGNOSTICS MARKET FOR NEXT-GENERATION SEQUENCING, BY REGION, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 98
NORTH AMERICA: TRANSPLANT DIAGNOSTICS MARKET FOR NEXT-GENERATION SEQUENCING, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 99
EUROPE: TRANSPLANT DIAGNOSTICS MARKET FOR NEXT-GENERATION SEQUENCING, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 100
ASIA PACIFIC: TRANSPLANT DIAGNOSTICSARKET FOR NEXT-GENERATION SEQUENCING, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 101
LATIN AMERICA: TRANSPLANT DIAGNOSTICS MARKET FOR NEXT-GENERATION SEQUENCING, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 102
MIDDLE EAST & AFRICA: TRANSPLANT DIAGNOSTICS MARKET FOR NEXT-GENERATION SEQUENCING, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 103
TRANSPLANT DIAGNOSTICS MARKET FOR OTHER SEQUENCING-BASED MOLECULAR ASSAYS, BY REGION, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 104
NORTH AMERICA: TRANSPLANT DIAGNOSTICS MARKET FOR OTHER SEQUENCING-BASED MOLECULAR ASSAYS, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 105
EUROPE: TRANSPLANT DIAGNOSTICS MARKET FOR OTHER SEQUENCING-BASED MOLECULAR ASSAYS, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 106
ASIA PACIFIC: TRANSPLANT DIAGNOSTICS MARKET FOR OTHER SEQUENCING-BASED MOLECULAR ASSAYS, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 107
LATIN AMERICA: TRANSPLANT DIAGNOSTICS MARKET FOR OTHER SEQUENCING-BASED MOLECULAR ASSAYS, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 108
MIDDLE EAST & AFRICA: TRANSPLANT DIAGNOSTICS MARKET FOR OTHER SEQUENCING-BASED MOLECULAR ASSAYS, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 109
TRANSPLANT DIAGNOSTICS MARKET FOR NON-MOLECULAR ASSAYS, BY REGION, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 110
NORTH AMERICA: TRANSPLANT DIAGNOSTICS MARKET FOR NON-MOLECULAR ASSAYS, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 111
EUROPE: TRANSPLANT DIAGNOSTICS MARKET FOR NON-MOLECULAR ASSAYS, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 112
ASIA PACIFIC: TRANSPLANT DIAGNOSTICS MARKET FOR NON-MOLECULAR ASSAYS, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 113
LATIN AMERICA: TRANSPLANT DIAGNOSTICS MARKET FOR NON-MOLECULAR ASSAYS, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 114
MIDDLE EAST & AFRICA: TRANSPLANT DIAGNOSTICS MARKET FOR NON-MOLECULAR ASSAYS, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 115
TRANSPLANT DIAGNOSTICS MARKET, BY APPLICATION, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 116
TRANSPLANT DIAGNOSTICS MARKET FOR DIAGNOSTIC APPLICATIONS, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 117
TRANSPLANT DIAGNOSTICS MARKET FOR DIAGNOSTIC APPLICATIONS, BY REGION, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 118
NORTH AMERICA: TRANSPLANT DIAGNOSTICS MARKET FOR DIAGNOSTIC APPLICATIONS, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 119
EUROPE: TRANSPLANT DIAGNOSTICS MARKET FOR DIAGNOSTIC APPLICATIONS, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 120
ASIA PACIFIC: TRANSPLANT DIAGNOSTICS MARKET FOR DIAGNOSTIC APPLICATIONS, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 121
LATIN AMERICA: TRANSPLANT DIAGNOSTICS MARKET FOR DIAGNOSTIC APPLICATIONS, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 122
MIDDLE EAST & AFRICA: TRANSPLANT DIAGNOSTICS MARKET FOR DIAGNOSTIC APPLICATIONS, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 123
TRANSPLANT DIAGNOSTICS MARKET FOR PRE-TRANSPLANTATION DIAGNOSTICS, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 124
TRANSPLANT DIAGNOSTICS MARKET FOR PRE-TRANSPLANTATION DIAGNOSTICS, BY REGION, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 125
NORTH AMERICA: TRANSPLANT DIAGNOSTICS MARKET FOR PRE-TRANSPLANTATION DIAGNOSTICS, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 126
EUROPE: TRANSPLANT DIAGNOSTICS MARKET FOR PRE-TRANSPLANTATION DIAGNOSTICS, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 127
ASIA PACIFIC: TRANSPLANT DIAGNOSTICS MARKET FOR PRE-TRANSPLANTATION DIAGNOSTICS, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 128
LATIN AMERICA: TRANSPLANT DIAGNOSTICS MARKET FOR PRE-TRANSPLANTATION DIAGNOSTICS, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 129
MIDDLE EAST & AFRICA: TRANSPLANT DIAGNOSTICS MARKET FOR PRE-TRANSPLANTATION DIAGNOSTICS, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 130
TRANSPLANT DIAGNOSTICS MARKET FOR INFECTIOUS DISEASE TESTING, BY REGION, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 131
NORTH AMERICA: TRANSPLANT DIAGNOSTICS MARKET FOR INFECTIOUS DISEASE TESTING, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 132
EUROPE: TRANSPLANT DIAGNOSTICS MARKET FOR INFECTIOUS DISEASE TESTING, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 133
ASIA PACIFIC: TRANSPLANT DIAGNOSTICS MARKET FOR INFECTIOUS DISEASE TESTING, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 134
LATIN AMERICA: TRANSPLANT DIAGNOSTICS MARKET FOR INFECTIOUS DISEASE TESTING, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 135
MIDDLE EAST & AFRICA: TRANSPLANT DIAGNOSTICS MARKET FOR INFECTIOUS DISEASE TESTING, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 136
TRANSPLANT DIAGNOSTICS MARKET FOR HISTOCOMPATIBILITY TESTING, BY REGION, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 137
NORTH AMERICA: TRANSPLANT DIAGNOSTICS MARKET FOR HISTOCOMPATIBILITY TESTING, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 138
EUROPE: TRANSPLANT DIAGNOSTICS MARKET FOR HISTOCOMPATIBILITY TESTING, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 139
ASIA PACIFIC: TRANSPLANT DIAGNOSTICS MARKET FOR HISTOCOMPATIBILITY TESTING, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 140
LATIN AMERICA: TRANSPLANT DIAGNOSTICS MARKET FOR HISTOCOMPATIBILITY TESTING, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 141
MIDDLE EAST & AFRICA: TRANSPLANT DIAGNOSTICS MARKET FOR HISTOCOMPATIBILITY TESTING, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 142
TRANSPLANT DIAGNOSTICS MARKET FOR BLOOD PROFILING, BY REGION, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 143
NORTH AMERICA: TRANSPLANT DIAGNOSTICS MARKET FOR BLOOD PROFILING, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 144
EUROPE: TRANSPLANT DIAGNOSTICS MARKET FOR BLOOD PROFILING, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 145
ASIA PACIFIC: TRANSPLANT DIAGNOSTICS MARKET FOR BLOOD PROFILING, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 146
LATIN AMERICA: TRANSPLANT DIAGNOSTICS MARKET FOR BLOOD PROFILING, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 147
MIDDLE EAST & AFRICA: TRANSPLANT DIAGNOSTICS MARKET FOR BLOOD PROFILING, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 148
TRANSPLANT DIAGNOSTICS MARKET FOR POST-TRANSPLANTATION DIAGNOSTICS, BY REGION, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 149
NORTH AMERICA: TRANSPLANT DIAGNOSTICS MARKET FOR POST-TRANSPLANTATION DIAGNOSTICS, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 150
EUROPE: TRANSPLANT DIAGNOSTICS MARKET FOR POST-TRANSPLANTATION DIAGNOSTICS, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 151
ASIA PACIFIC: TRANSPLANT DIAGNOSTICS MARKET FOR POST-TRANSPLANTATION DIAGNOSTICS, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 152
LATIN AMERICA: TRANSPLANT DIAGNOSTICS MARKET FOR POST-TRANSPLANTATION DIAGNOSTICS, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 153
MIDDLE EAST & AFRICA: TRANSPLANT DIAGNOSTICS MARKET FOR POST-TRANSPLANTATION DIAGNOSTICS, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 154
TRANSPLANT DIAGNOSTICS MARKET FOR RESEARCH APPLICATIONS, BY REGION, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 155
NORTH AMERICA: TRANSPLANT DIAGNOSTICS MARKET FOR RESEARCH APPLICATIONS, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 156
EUROPE: TRANSPLANT DIAGNOSTICS MARKET FOR RESEARCH APPLICATIONS, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 157
ASIA PACIFIC: TRANSPLANT DIAGNOSTICS MARKET FOR RESEARCH APPLICATIONS, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 158
LATIN AMERICA: TRANSPLANT DIAGNOSTICS MARKET FOR RESEARCH APPLICATIONS, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 159
MIDDLE EAST & AFRICA: TRANSPLANT DIAGNOSTICS MARKET FOR RESEARCH APPLICATIONS, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 160
TRANSPLANT DIAGNOSTICS MARKET, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 161
TRANSPLANT DIAGNOSTICS MARKET FOR SOLID ORGAN TRANSPLANTATION, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 162
TRANSPLANT DIAGNOSTICS MARKET FOR SOLID ORGAN TRANSPLANTATION, BY REGION, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 163
NORTH AMERICA: TRANSPLANT DIAGNOSTICS MARKET FOR SOLID ORGAN TRANSPLANTATION, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 164
EUROPE: TRANSPLANT DIAGNOSTICS MARKET FOR SOLID ORGAN TRANSPLANTATION, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 165
ASIA PACIFIC: TRANSPLANT DIAGNOSTICS MARKET FOR SOLID ORGAN TRANSPLANTATION, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 166
LATIN AMERICA: TRANSPLANT DIAGNOSTICS MARKET FOR SOLID ORGAN TRANSPLANTATION, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 167
MIDDLE EAST & AFRICA: TRANSPLANT DIAGNOSTICS MARKET FOR SOLID ORGAN TRANSPLANTATION, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 168
TRANSPLANT DIAGNOSTICS MARKET FOR KIDNEY TRANSPLANTATION, BY REGION, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 169
NORTH AMERICA: TRANSPLANT DIAGNOSTICS MARKET FOR KIDNEY TRANSPLANTATION, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 170
EUROPE: TRANSPLANT DIAGNOSTICS MARKET FOR KIDNEY TRANSPLANTATION, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 171
ASIA PACIFIC: TRANSPLANT DIAGNOSTICS MARKET FOR KIDNEY TRANSPLANTATION, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 172
LATIN AMERICA: TRANSPLANT DIAGNOSTICS MARKET FOR KIDNEY TRANSPLANTATION, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 173
MIDDLE EAST & AFRICA: TRANSPLANT DIAGNOSTICS MARKET FOR KIDNEY TRANSPLANTATION, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 174
TRANSPLANT DIAGNOSTICS MARKET FOR LIVER TRANSPLANTATION, BY REGION, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 175
NORTH AMERICA: TRANSPLANT DIAGNOSTICS MARKET FOR LIVER TRANSPLANTATION, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 176
EUROPE: TRANSPLANT DIAGNOSTICS MARKET FOR LIVER TRANSPLANTATION, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 177
ASIA PACIFIC: TRANSPLANT DIAGNOSTICS MARKET FOR LIVER TRANSPLANTATION, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 178
LATIN AMERICA: TRANSPLANT DIAGNOSTICS MARKET FOR LIVER TRANSPLANTATION, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 179
MIDDLE EAST & AFRICA: TRANSPLANT DIAGNOSTICS MARKET FOR LIVER TRANSPLANTATION, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 180
TRANSPLANT DIAGNOSTICS MARKET FOR LUNG TRANSPLANTATION, BY REGION, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 181
NORTH AMERICA: TRANSPLANT DIAGNOSTICS MARKET FOR LUNG TRANSPLANTATION, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 182
EUROPE: TRANSPLANT DIAGNOSTICS MARKET FOR LUNG TRANSPLANTATION, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 183
ASIA PACIFIC: TRANSPLANT DIAGNOSTICS MARKET FOR LUNG TRANSPLANTATION, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 184
LATIN AMERICA: TRANSPLANT DIAGNOSTICS MARKET FOR LUNG TRANSPLANTATION, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 185
MIDDLE EAST & AFRICA: TRANSPLANT DIAGNOSTICS MARKET FOR LUNG TRANSPLANTATION, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 186
TRANSPLANT DIAGNOSTICS MARKET FOR HEART TRANSPLANTATION, BY REGION, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 187
NORTH AMERICA: TRANSPLANT DIAGNOSTICS MARKET FOR HEART TRANSPLANTATION, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 188
EUROPE: TRANSPLANT DIAGNOSTICS MARKET FOR HEART TRANSPLANTATION, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 189
ASIA PACIFIC: TRANSPLANT DIAGNOSTICS MARKET FOR HEART TRANSPLANTATION, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 190
LATIN AMERICA: TRANSPLANT DIAGNOSTICS MARKET FOR HEART TRANSPLANTATION, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 191
MIDDLE EAST & AFRICA: TRANSPLANT DIAGNOSTICS MARKET FOR HEART TRANSPLANTATION, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 192
TRANSPLANT DIAGNOSTICS MARKET FOR PANCREAS TRANSPLANTATION, BY REGION, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 193
NORTH AMERICA: TRANSPLANT DIAGNOSTICS MARKET FOR PANCREAS TRANSPLANTATION, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 194
EUROPE: TRANSPLANT DIAGNOSTICS MARKET FOR PANCREAS TRANSPLANTATION, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 195
ASIA PACIFIC: TRANSPLANT DIAGNOSTICS MARKET FOR PANCREAS TRANSPLANTATION, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 196
LATIN AMERICA: TRANSPLANT DIAGNOSTICS MARKET FOR PANCREAS TRANSPLANTATION, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 197
MIDDLE EAST & AFRICA: TRANSPLANT DIAGNOSTICS MARKET FOR PANCREAS TRANSPLANTATION, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 198
TRANSPLANT DIAGNOSTICS MARKET FOR OTHER SOLID ORGAN TRANSPLANTATION, BY REGION, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 199
NORTH AMERICA: TRANSPLANT DIAGNOSTICS MARKET FOR OTHER SOLID ORGAN TRANSPLANTATION, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 200
EUROPE: TRANSPLANT DIAGNOSTICS MARKET FOR OTHER SOLID ORGAN TRANSPLANTATION, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 201
ASIA PACIFIC: TRANSPLANT DIAGNOSTICS MARKET FOR OTHER SOLID ORGAN TRANSPLANTATION, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 202
LATIN AMERICA: TRANSPLANT DIAGNOSTICS MARKET FOR OTHER SOLID ORGAN TRANSPLANTATION, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 203
MIDDLE EAST & AFRICA: TRANSPLANT DIAGNOSTICS MARKET FOR OTHER SOLID ORGAN TRANSPLANTATION, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 204
TRANSPLANT DIAGNOSTICS MARKET FOR STEM CELL TRANSPLANTATION, BY REGION, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 205
NORTH AMERICA: TRANSPLANT DIAGNOSTICS MARKET FOR STEM CELL TRANSPLANTATION, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 206
EUROPE: TRANSPLANT DIAGNOSTICS MARKET FOR STEM CELL TRANSPLANTATION, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 207
ASIA PACIFIC: TRANSPLANT DIAGNOSTICS MARKET FOR STEM CELL TRANSPLANTATION, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 208
LATIN AMERICA: TRANSPLANT DIAGNOSTICS MARKET FOR STEM CELL TRANSPLANTATION, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 209
MIDDLE EAST & AFRICA: TRANSPLANT DIAGNOSTICS MARKET FOR STEM CELL TRANSPLANTATION, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 210
TRANSPLANT DIAGNOSTICS MARKET FOR SOFT TISSUE TRANSPLANTATION, BY REGION, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 211
NORTH AMERICA: TRANSPLANT DIAGNOSTICS MARKET FOR SOFT TISSUE TRANSPLANTATION, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 212
EUROPE: TRANSPLANT DIAGNOSTICS MARKET FOR SOFT TISSUE TRANSPLANTATION, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 213
ASIA PACIFIC: TRANSPLANT DIAGNOSTICS MARKET FOR SOFT TISSUE TRANSPLANTATION, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 214
LATIN AMERICA: TRANSPLANT DIAGNOSTICS MARKET FOR SOFT TISSUE TRANSPLANTATION, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 215
MIDDLE EAST & AFRICA: TRANSPLANT DIAGNOSTICS MARKET FOR SOFT TISSUE TRANSPLANTATION, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 216
TRANSPLANT DIAGNOSTICS MARKET FOR BONE MARROW TRANSPLANTATION, BY REGION, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 217
NORTH AMERICA: TRANSPLANT DIAGNOSTICS MARKET FOR BONE MARROW TRANSPLANTATION, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 218
EUROPE: TRANSPLANT DIAGNOSTICS MARKET FOR BONE MARROW TRANSPLANTATION, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 219
ASIA PACIFIC: TRANSPLANT DIAGNOSTICS MARKET FOR BONE MARROW TRANSPLANTATION, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 220
LATIN AMERICA: TRANSPLANT DIAGNOSTICS MARKET FOR BONE MARROW TRANSPLANTATION, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 221
MIDDLE EAST & AFRICA: TRANSPLANT DIAGNOSTICS MARKET FOR BONE MARROW TRANSPLANTATION, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 222
TRANSPLANT DIAGNOSTICS MARKET, BY END USER, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 223
TRANSPLANT DIAGNOSTICS MARKET FOR INDEPENDENT REFERENCE LABORATORIES, BY REGION, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 224
NORTH AMERICA: TRANSPLANT DIAGNOSTICS MARKET FOR INDEPENDENT REFERENCE LABORATORIES, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 225
EUROPE: TRANSPLANT DIAGNOSTICS MARKET FOR INDEPENDENT REFERENCE LABORATORIES, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 226
ASIA PACIFIC: TRANSPLANT DIAGNOSTICS MARKET FOR INDEPENDENT REFERENCE LABORATORIES, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 227
LATIN AMERICA: TRANSPLANT DIAGNOSTICS MARKET FOR INDEPENDENT REFERENCE LABORATORIES, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 228
MIDDLE EAST & AFRICA: TRANSPLANT DIAGNOSTICS MARKET FOR INDEPENDENT REFERENCE LABORATORIES, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 229
TRANSPLANT DIAGNOSTICS MARKET FOR HOSPITALS & TRANSPLANT CENTERS, BY REGION, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 230
NORTH AMERICA: TRANSPLANT DIAGNOSTICS MARKET FOR HOSPITALS & TRANSPLANT CENTERS, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 231
EUROPE: TRANSPLANT DIAGNOSTICS MARKET FOR HOSPITALS & TRANSPLANT CENTERS, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 232
ASIA PACIFIC: TRANSPLANT DIAGNOSTICS MARKET FOR HOSPITALS & TRANSPLANT CENTERS, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 233
LATIN AMERICA: TRANSPLANT DIAGNOSTICS MARKET FOR HOSPITALS & TRANSPLANT CENTERS, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 234
MIDDLE EAST & AFRICA: TRANSPLANT DIAGNOSTICS MARKET FOR HOSPITALS & TRANSPLANT CENTERS, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 235
TRANSPLANT DIAGNOSTICS MARKET FOR RESEARCH LABORATORIES & ACADEMIC INSTITUTES, BY REGION, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 236
NORTH AMERICA: TRANSPLANT DIAGNOSTICS MARKET FOR RESEARCH LABORATORIES & ACADEMIC INSTITUTES, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 237
EUROPE: TRANSPLANT DIAGNOSTICS MARKET FOR RESEARCH LABORATORIES & ACADEMIC INSTITUTES, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 238
ASIA PACIFIC: TRANSPLANT DIAGNOSTICS MARKET FOR RESEARCH LABORATORIES & ACADEMIC INSTITUTES, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 239
LATIN AMERICA: TRANSPLANT DIAGNOSTICS MARKET FOR RESEARCH LABORATORIES & ACADEMIC INSTITUTES, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 240
MIDDLE EAST & AFRICA: TRANSPLANT DIAGNOSTICS MARKET FOR RESEARCH LABORATORIES & ACADEMIC INSTITUTES, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 241
TRANSPLANT DIAGNOSTICS, BY REGION, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 242
NORTH AMERICA: MACROECONOMIC INDICATORS
 
 
 
 
 
 
TABLE 243
NORTH AMERICA: TRANSPLANT DIAGNOSTICS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 244
NORTH AMERICA: TRANSPLANT DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 245
NORTH AMERICA: TRANSPLANT DIAGNOSTICS MARKET, BY TECHNOLOGY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 246
NORTH AMERICA: TRANSPLANT DIAGNOSTICS MARKET FOR MOLECULAR ASSAYS, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 247
NORTH AMERICA: TRANSPLANT DIAGNOSTICS MARKET FOR PCR-BASED MOLECULAR ASSAYS, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 248
NORTH AMERICA: TRANSPLANT DIAGNOSTICS MARKET FOR SEQUENCING-BASED MOLECULAR ASSAYS, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 249
NORTH AMERICA: TRANSPLANT DIAGNOSTICS MARKET, BY APPLICATION, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 250
NORTH AMERICA: TRANSPLANT DIAGNOSTICS MARKET FOR DIAGNOSTIC APPLICATIONS, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 251
NORTH AMERICA: TRANSPLANT DIAGNOSTICS MARKET FOR PRE-TRANSPLANTATION DIAGNOSTICS, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 252
NORTH AMERICA: TRANSPLANT DIAGNOSTICS MARKET, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 253
NORTH AMERICA: TRANSPLANT DIAGNOSTICS MARKET FOR SOLID ORGAN TRANSPLANTATION, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 254
NORTH AMERICA: TRANSPLANT DIAGNOSTICS MARKET, BY END USER, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 255
US: TRANSPLANT DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 256
US: TRANSPLANT DIAGNOSTICS MARKET, BY TECHNOLOGY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 257
US: TRANSPLANT DIAGNOSTICS MARKET FOR MOLECULAR ASSAYS, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 258
US: TRANSPLANT DIAGNOSTICS MARKET FOR PCR-BASED MOLECULAR ASSAYS, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 259
US: TRANSPLANT DIAGNOSTICS MARKET FOR SEQUENCING-BASED MOLECULAR ASSAYS, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 260
US: TRANSPLANT DIAGNOSTICS MARKET, BY APPLICATION, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 261
US: TRANSPLANT DIAGNOSTICS MARKET FOR DIAGNOSTIC APPLICATIONS, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 262
US: TRANSPLANT DIAGNOSTICS MARKET FOR PRE-TRANSPLANTATION DIAGNOSTICS, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 263
US: TRANSPLANT DIAGNOSTICS MARKET, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 264
US: TRANSPLANT DIAGNOSTICS MARKET FOR SOLID ORGAN TRANSPLANTATION, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 265
US: TRANSPLANT DIAGNOSTICS MARKET, BY END USER, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 266
CANADA: TRANSPLANT DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 267
CANADA: TRANSPLANT DIAGNOSTICS MARKET, BY TECHNOLOGY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 268
CANADA: TRANSPLANT DIAGNOSTICS MARKET FOR MOLECULAR ASSAYS, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 269
CANADA: TRANSPLANT DIAGNOSTICS MARKET FOR PCR-BASED MOLECULAR ASSAYS, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 270
CANADA: TRANSPLANT DIAGNOSTICS MARKET FOR SEQUENCING-BASED MOLECULAR ASSAYS, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 271
CANADA: TRANSPLANT DIAGNOSTICS MARKET, BY APPLICATION, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 272
CANADA: TRANSPLANT DIAGNOSTICS MARKET FOR DIAGNOSTIC APPLICATIONS, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 273
CANADA: TRANSPLANT DIAGNOSTICS MARKET FOR PRE-TRANSPLANTATION DIAGNOSTICS, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 274
CANADA: TRANSPLANT DIAGNOSTICS MARKET, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 275
CANADA: TRANSPLANT DIAGNOSTICS MARKET FOR SOLID ORGAN TRANSPLANTATION, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 276
CANADA: TRANSPLANT DIAGNOSTICS MARKET, BY END USER, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 277
MACROECONOMIC INDICATORS FOR EUROPE
 
 
 
 
 
 
TABLE 278
EUROPE: TRANSPLANT DIAGNOSTICS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 279
EUROPE: TRANSPLANT DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 280
EUROPE: TRANSPLANT DIAGNOSTICS MARKET, BY TECHNOLOGY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 281
EUROPE: TRANSPLANT DIAGNOSTICS MARKET FOR MOLECULAR ASSAYS, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 282
EUROPE: TRANSPLANT DIAGNOSTICS MARKET FOR PCR-BASED MOLECULAR ASSAYS, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 283
EUROPE: TRANSPLANT DIAGNOSTICS MARKET FOR SEQUENCING-BASED MOLECULAR ASSAYS, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 284
EUROPE: TRANSPLANT DIAGNOSTICS MARKET, BY APPLICATION, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 285
EUROPE: TRANSPLANT DIAGNOSTICS MARKET FOR DIAGNOSTIC APPLICATIONS, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 286
EUROPE: TRANSPLANT DIAGNOSTICS MARKET FOR PRE-TRANSPLANTATION DIAGNOSTICS, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 287
EUROPE: TRANSPLANT DIAGNOSTICS MARKET, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 288
EUROPE: TRANSPLANT DIAGNOSTICS MARKET FOR SOLID ORGAN TRANSPLANTATION, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 289
EUROPE: TRANSPLANT DIAGNOSTICS MARKET, BY END USER, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 290
GERMANY: TRANSPLANT DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 291
GERMANY: TRANSPLANT DIAGNOSTICS MARKET, BY TECHNOLOGY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 292
GERMANY: TRANSPLANT DIAGNOSTICS MARKET FOR MOLECULAR ASSAYS, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 293
GERMANY: TRANSPLANT DIAGNOSTICS MARKET FOR PCR-BASED MOLECULAR ASSAYS, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 294
GERMANY: TRANSPLANT DIAGNOSTICS MARKET FOR SEQUENCING-BASED MOLECULAR ASSAYS, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 295
GERMANY: TRANSPLANT DIAGNOSTICS MARKET, BY APPLICATION, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 296
GERMANY: TRANSPLANT DIAGNOSTICS MARKET FOR DIAGNOSTIC APPLICATIONS, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 297
GERMANY: TRANSPLANT DIAGNOSTICS MARKET FOR PRE-TRANSPLANTATION DIAGNOSTICS, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 298
GERMANY: TRANSPLANT DIAGNOSTICS MARKET, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 299
GERMANY: TRANSPLANT DIAGNOSTICS MARKET FOR SOLID ORGAN TRANSPLANTATION, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 300
GERMANY: TRANSPLANT DIAGNOSTICS MARKET, BY END USER, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 301
UK: TRANSPLANT DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 302
UK: TRANSPLANT DIAGNOSTICS MARKET, BY TECHNOLOGY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 303
UK: TRANSPLANT DIAGNOSTICS MARKET FOR MOLECULAR ASSAYS, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 304
UK: TRANSPLANT DIAGNOSTICS MARKET FOR PCR-BASED MOLECULAR ASSAYS, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 305
UK: TRANSPLANT DIAGNOSTICS MARKET FOR SEQUENCING-BASED MOLECULAR ASSAYS, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 306
UK: TRANSPLANT DIAGNOSTICS MARKET, BY APPLICATION, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 307
UK: TRANSPLANT DIAGNOSTICS MARKET FOR DIAGNOSTIC APPLICATIONS, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 308
UK: TRANSPLANT DIAGNOSTICS MARKET FOR PRE-TRANSPLANTATION DIAGNOSTICS, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 309
UK: TRANSPLANT DIAGNOSTICS MARKET, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 310
UK: TRANSPLANT DIAGNOSTICS MARKET FOR SOLID ORGAN TRANSPLANTATION, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 311
UK: TRANSPLANT DIAGNOSTICS MARKET, BY END USER, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 312
FRANCE: TRANSPLANT DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 313
FRANCE: TRANSPLANT DIAGNOSTICS MARKET, BY TECHNOLOGY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 314
FRANCE: TRANSPLANT DIAGNOSTICS MARKET FOR MOLECULAR ASSAYS, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 315
FRANCE: TRANSPLANT DIAGNOSTICS MARKET FOR PCR-BASED MOLECULAR ASSAYS, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 316
FRANCE: TRANSPLANT DIAGNOSTICS MARKET FOR SEQUENCING-BASED MOLECULAR ASSAYS, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 317
FRANCE: TRANSPLANT DIAGNOSTICS MARKET, BY APPLICATION, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 318
FRANCE: TRANSPLANT DIAGNOSTICS MARKET FOR DIAGNOSTIC APPLICATIONS, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 319
FRANCE: TRANSPLANT DIAGNOSTICS MARKET FOR PRE-TRANSPLANTATION DIAGNOSTICS, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 320
FRANCE: TRANSPLANT DIAGNOSTICS MARKET, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 321
FRANCE: TRANSPLANT DIAGNOSTICS MARKET FOR SOLID ORGAN TRANSPLANTATION, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 322
FRANCE: TRANSPLANT DIAGNOSTICS MARKET, BY END USER, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 323
ITALY: TRANSPLANT DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 324
ITALY: TRANSPLANT DIAGNOSTICS MARKET, BY TECHNOLOGY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 325
ITALY: TRANSPLANT DIAGNOSTICS MARKET FOR MOLECULAR ASSAYS, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 326
ITALY: TRANSPLANT DIAGNOSTICS MARKET FOR PCR-BASED MOLECULAR ASSAYS, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 327
ITALY: TRANSPLANT DIAGNOSTICS MARKET FOR SEQUENCING-BASED MOLECULAR ASSAYS, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 328
ITALY: TRANSPLANT DIAGNOSTICS MARKET, BY APPLICATION, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 329
ITALY: TRANSPLANT DIAGNOSTICS MARKET FOR DIAGNOSTIC APPLICATIONS, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 330
ITALY: TRANSPLANT DIAGNOSTICS MARKET FOR PRE-TRANSPLANTATION DIAGNOSTICS, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 331
ITALY: TRANSPLANT DIAGNOSTICS MARKET, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 332
ITALY: TRANSPLANT DIAGNOSTICS MARKET FOR SOLID ORGAN TRANSPLANTATION, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 333
ITALY: TRANSPLANT DIAGNOSTICS MARKET, BY END USER, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 334
SPAIN: TRANSPLANT DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 335
SPAIN: TRANSPLANT DIAGNOSTICS MARKET, BY TECHNOLOGY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 336
SPAIN: TRANSPLANT DIAGNOSTICS MARKET FOR MOLECULAR ASSAYS, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 337
SPAIN: TRANSPLANT DIAGNOSTICS MARKET FOR PCR-BASED MOLECULAR ASSAYS, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 338
SPAIN: TRANSPLANT DIAGNOSTICS MARKET FOR SEQUENCING-BASED MOLECULAR ASSAYS, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 339
SPAIN: TRANSPLANT DIAGNOSTICS MARKET, BY APPLICATION, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 340
SPAIN: TRANSPLANT DIAGNOSTICS MARKET FOR DIAGNOSTIC APPLICATIONS, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 341
SPAIN: TRANSPLANT DIAGNOSTICS MARKET FOR PRE-TRANSPLANTATION DIAGNOSTICS, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 342
SPAIN: TRANSPLANT DIAGNOSTICS MARKET, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 343
SPAIN: TRANSPLANT DIAGNOSTICS MARKET FOR SOLID ORGAN TRANSPLANTATION, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 344
SPAIN: TRANSPLANT DIAGNOSTICS MARKET, BY END USER, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 345
REST OF EUROPE: TRANSPLANT DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 346
REST OF EUROPE: TRANSPLANT DIAGNOSTICS MARKET, BY TECHNOLOGY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 347
REST OF EUROPE: TRANSPLANT DIAGNOSTICS MARKET FOR MOLECULAR ASSAYS, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 348
REST OF EUROPE: TRANSPLANT DIAGNOSTICS MARKET FOR PCR-BASED MOLECULAR ASSAYS, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 349
REST OF EUROPE: TRANSPLANT DIAGNOSTICS MARKET FOR SEQUENCING-BASED MOLECULAR ASSAYS, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 350
REST OF EUROPE: TRANSPLANT DIAGNOSTICS MARKET, BY APPLICATION, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 351
REST OF EUROPE: TRANSPLANT DIAGNOSTICS MARKET FOR DIAGNOSTIC APPLICATIONS, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 352
REST OF EUROPE: TRANSPLANT DIAGNOSTICS MARKET FOR PRE-TRANSPLANTATION DIAGNOSTICS, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 353
REST OF EUROPE: TRANSPLANT DIAGNOSTICS MARKET, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 354
REST OF EUROPE: TRANSPLANT DIAGNOSTICS MARKET FOR SOLID ORGAN TRANSPLANTATION, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 355
REST OF EUROPE: TRANSPLANT DIAGNOSTICS MARKET, BY END USER, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 356
MACROECONOMIC INDICATORS FOR ASIA PACIFIC
 
 
 
 
 
 
TABLE 357
ASIA PACIFIC: TRANSPLANT DIAGNOSTICS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 358
ASIA PACIFIC: TRANSPLANT DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 359
ASIA PACIFIC: TRANSPLANT DIAGNOSTICS MARKET, BY TECHNOLOGY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 360
ASIA PACIFIC: TRANSPLANT DIAGNOSTICS MARKET FOR MOLECULAR ASSAYS, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 361
ASIA PACIFIC: TRANSPLANT DIAGNOSTICS MARKET FOR PCR-BASED MOLECULAR ASSAYS, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 362
ASIA PACIFIC: TRANSPLANT DIAGNOSTICS MARKET FOR SEQUENCING-BASED MOLECULAR ASSAYS, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 363
ASIA PACIFIC: TRANSPLANT DIAGNOSTICS MARKET, BY APPLICATION, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 364
ASIA PACIFIC: TRANSPLANT DIAGNOSTICS MARKET FOR DIAGNOSTIC APPLICATIONS, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 365
ASIA PACIFIC: TRANSPLANT DIAGNOSTICS MARKET FOR PRE-TRANSPLANTATION DIAGNOSTICS, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 366
ASIA PACIFIC: TRANSPLANT DIAGNOSTICS MARKET, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 367
ASIA PACIFIC: TRANSPLANT DIAGNOSTICS MARKET FOR SOLID ORGAN TRANSPLANTATION, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 368
ASIA PACIFIC: TRANSPLANT DIAGNOSTICS MARKET, BY END USER, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 369
CHINA: TRANSPLANT DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 370
CHINA: TRANSPLANT DIAGNOSTICS MARKET, BY TECHNOLOGY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 371
CHINA: TRANSPLANT DIAGNOSTICS MARKET FOR MOLECULAR ASSAYS, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 372
CHINA: TRANSPLANT DIAGNOSTICS MARKET FOR PCR-BASED MOLECULAR ASSAYS, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 373
CHINA: TRANSPLANT DIAGNOSTICS MARKET FOR SEQUENCING-BASED MOLECULAR ASSAYS, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 374
CHINA: TRANSPLANT DIAGNOSTICS MARKET, BY APPLICATION, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 375
CHINA: TRANSPLANT DIAGNOSTICS MARKET FOR DIAGNOSTIC APPLICATIONS, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 376
CHINA: TRANSPLANT DIAGNOSTICS MARKET FOR PRE-TRANSPLANTATION DIAGNOSTICS, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 377
CHINA: TRANSPLANT DIAGNOSTICS MARKET, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 378
CHINA: TRANSPLANT DIAGNOSTICS MARKET FOR SOLID ORGAN TRANSPLANTATION, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 379
CHINA: TRANSPLANT DIAGNOSTICS MARKET, BY END USER, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 380
JAPAN: TRANSPLANT DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 381
JAPAN: TRANSPLANT DIAGNOSTICS MARKET, BY TECHNOLOGY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 382
JAPAN: TRANSPLANT DIAGNOSTICS MARKET FOR MOLECULAR ASSAYS, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 383
JAPAN: TRANSPLANT DIAGNOSTICS MARKET FOR PCR-BASED MOLECULAR ASSAYS, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 384
JAPAN: TRANSPLANT DIAGNOSTICS MARKET FOR SEQUENCING-BASED MOLECULAR ASSAYS, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 385
JAPAN: TRANSPLANT DIAGNOSTICS MARKET, BY APPLICATION, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 386
JAPAN: TRANSPLANT DIAGNOSTICS MARKET FOR DIAGNOSTIC APPLICATIONS, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 387
JAPAN: TRANSPLANT DIAGNOSTICS MARKET FOR PRE-TRANSPLANTATION DIAGNOSTICS, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 388
JAPAN: TRANSPLANT DIAGNOSTICS MARKET, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 389
JAPAN: TRANSPLANT DIAGNOSTICS MARKET FOR SOLID ORGAN TRANSPLANTATION, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 390
JAPAN: TRANSPLANT DIAGNOSTICS MARKET, BY END USER, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 391
INDIA: TRANSPLANT DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 392
INDIA: TRANSPLANT DIAGNOSTICS MARKET, BY TECHNOLOGY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 393
INDIA: TRANSPLANT DIAGNOSTICS MARKET FOR MOLECULAR ASSAYS, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 394
INDIA: TRANSPLANT DIAGNOSTICS MARKET FOR PCR-BASED MOLECULAR ASSAYS, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 395
INDIA: TRANSPLANT DIAGNOSTICS MARKET FOR SEQUENCING-BASED MOLECULAR ASSAYS, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 396
INDIA: TRANSPLANT DIAGNOSTICS MARKET, BY APPLICATION, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 397
INDIA: TRANSPLANT DIAGNOSTICS MARKET FOR DIAGNOSTIC APPLICATIONS, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 398
INDIA: TRANSPLANT DIAGNOSTICS MARKET FOR PRE-TRANSPLANTATION DIAGNOSTICS, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 399
INDIA: TRANSPLANT DIAGNOSTICS MARKET, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 400
INDIA: TRANSPLANT DIAGNOSTICS MARKET FOR SOLID ORGAN TRANSPLANTATION, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 401
INDIA: TRANSPLANT DIAGNOSTICS MARKET, BY END USER, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 402
AUSTRALIA: TRANSPLANT DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 403
AUSTRALIA: TRANSPLANT DIAGNOSTICS MARKET, BY TECHNOLOGY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 404
AUSTRALIA: TRANSPLANT DIAGNOSTICS MARKET FOR MOLECULAR ASSAYS, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 405
AUSTRALIA: TRANSPLANT DIAGNOSTICS MARKET FOR PCR-BASED MOLECULAR ASSAYS, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 406
AUSTRALIA: TRANSPLANT DIAGNOSTICS MARKET FOR SEQUENCING-BASED MOLECULAR ASSAYS, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 407
AUSTRALIA: TRANSPLANT DIAGNOSTICS MARKET, BY APPLICATION, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 408
AUSTRALIA: TRANSPLANT DIAGNOSTICS MARKET FOR DIAGNOSTIC APPLICATIONS, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 409
AUSTRALIA: TRANSPLANT DIAGNOSTICS MARKET FOR PRE-TRANSPLANTATION DIAGNOSTICS, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 410
AUSTRALIA: TRANSPLANT DIAGNOSTICS MARKET, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 411
AUSTRALIA: TRANSPLANT DIAGNOSTICS MARKET FOR SOLID ORGAN TRANSPLANTATION, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 412
AUSTRALIA: TRANSPLANT DIAGNOSTICS MARKET, BY END USER, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 413
SOUTH KOREA: TRANSPLANT DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 414
SOUTH KOREA: TRANSPLANT DIAGNOSTICS MARKET, BY TECHNOLOGY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 415
SOUTH KOREA: TRANSPLANT DIAGNOSTICS MARKET FOR MOLECULAR ASSAYS, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 416
SOUTH KOREA: TRANSPLANT DIAGNOSTICS MARKET FOR PCR-BASED MOLECULAR ASSAYS, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 417
SOUTH KOREA: TRANSPLANT DIAGNOSTICS MARKET FOR SEQUENCING-BASED MOLECULAR ASSAYS, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 418
SOUTH KOREA: TRANSPLANT DIAGNOSTICS MARKET, BY APPLICATION, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 419
SOUTH KOREA: TRANSPLANT DIAGNOSTICS MARKET FOR DIAGNOSTIC APPLICATIONS, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 420
SOUTH KOREA: TRANSPLANT DIAGNOSTICS MARKET FOR PRE-TRANSPLANTATION DIAGNOSTICS, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 421
SOUTH KOREA: TRANSPLANT DIAGNOSTICS MARKET, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 422
SOUTH KOREA: TRANSPLANT DIAGNOSTICS MARKET FOR SOLID ORGAN TRANSPLANTATION, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 423
SOUTH KOREA: TRANSPLANT DIAGNOSTICS MARKET, BY END USER, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 424
REST OF ASIA PACIFIC: TRANSPLANT DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 425
REST OF ASIA PACIFIC: TRANSPLANT DIAGNOSTICS MARKET, BY TECHNOLOGY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 426
REST OF ASIA PACIFIC: TRANSPLANT DIAGNOSTICS MARKET FOR MOLECULAR ASSAYS, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 427
REST OF ASIA PACIFIC: TRANSPLANT DIAGNOSTICS MARKET FOR PCR-BASED MOLECULAR ASSAYS, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 428
REST OF ASIA PACIFIC: TRANSPLANT DIAGNOSTICS MARKET FOR SEQUENCING-BASED MOLECULAR ASSAYS, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 429
REST OF ASIA PACIFIC: TRANSPLANT DIAGNOSTICS MARKET, BY APPLICATION, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 430
REST OF ASIA PACIFIC: TRANSPLANT DIAGNOSTICS MARKET FOR DIAGNOSTIC APPLICATIONS, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 431
REST OF ASIA PACIFIC: TRANSPLANT DIAGNOSTICS MARKET FOR PRE-TRANSPLANTATION DIAGNOSTICS, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 432
REST OF ASIA PACIFIC: TRANSPLANT DIAGNOSTICS MARKET, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 433
REST OF ASIA PACIFIC: TRANSPLANT DIAGNOSTICS MARKET FOR SOLID ORGAN TRANSPLANTATION, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 434
REST OF ASIA PACIFIC: TRANSPLANT DIAGNOSTICS MARKET, BY END USER, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 435
MACROECONOMIC INDICATORS FOR LATIN AMERICA
 
 
 
 
 
 
TABLE 436
LATIN AMERICA: TRANSPLANT DIAGNOSTICS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 437
LATIN AMERICA: TRANSPLANT DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 438
LATIN AMERICA: TRANSPLANT DIAGNOSTICS MARKET, BY TECHNOLOGY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 439
LATIN AMERICA: TRANSPLANT DIAGNOSTICS MARKET FOR MOLECULAR ASSAYS, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 440
LATIN AMERICA: TRANSPLANT DIAGNOSTICS MARKET FOR PCR-BASED MOLECULAR ASSAYS, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 441
LATIN AMERICA: TRANSPLANT DIAGNOSTICS MARKET FOR SEQUENCING-BASED MOLECULAR ASSAYS, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 442
LATIN AMERICA: TRANSPLANT DIAGNOSTICS MARKET, BY APPLICATION, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 443
LATIN AMERICA: TRANSPLANT DIAGNOSTICS MARKET FOR DIAGNOSTIC APPLICATIONS, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 444
LATIN AMERICA: TRANSPLANT DIAGNOSTICS MARKET FOR PRE-TRANSPLANTATION DIAGNOSTICS, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 445
LATIN AMERICA: TRANSPLANT DIAGNOSTICS MARKET, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 446
LATIN AMERICA: TRANSPLANT DIAGNOSTICS MARKET FOR SOLID ORGAN TRANSPLANTATION, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 447
LATIN AMERICA: TRANSPLANT DIAGNOSTICS MARKET, BY END USER, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 448
BRAZIL: TRANSPLANT DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 449
BRAZIL: TRANSPLANT DIAGNOSTICS MARKET, BY TECHNOLOGY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 450
BRAZIL: TRANSPLANT DIAGNOSTICS MARKET FOR MOLECULAR ASSAYS, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 451
BRAZIL: TRANSPLANT DIAGNOSTICS MARKET FOR PCR-BASED MOLECULAR ASSAYS, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 452
BRAZIL: TRANSPLANT DIAGNOSTICS MARKET FOR SEQUENCING-BASED MOLECULAR ASSAYS, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 453
BRAZIL: TRANSPLANT DIAGNOSTICS MARKET, BY APPLICATION, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 454
BRAZIL: TRANSPLANT DIAGNOSTICS MARKET FOR DIAGNOSTIC APPLICATIONS, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 455
BRAZIL: TRANSPLANT DIAGNOSTICS MARKET FOR PRE-TRANSPLANTATION DIAGNOSTICS, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 456
BRAZIL: TRANSPLANT DIAGNOSTICS MARKET, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 457
BRAZIL: TRANSPLANT DIAGNOSTICS MARKET FOR SOLID ORGAN TRANSPLANTATION, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 458
BRAZIL: TRANSPLANT DIAGNOSTICS MARKET, BY END USER, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 459
MEXICO: TRANSPLANT DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 460
MEXICO: TRANSPLANT DIAGNOSTICS MARKET, BY TECHNOLOGY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 461
MEXICO: TRANSPLANT DIAGNOSTICS MARKET FOR MOLECULAR ASSAYS, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 462
MEXICO: TRANSPLANT DIAGNOSTICS MARKET FOR PCR-BASED MOLECULAR ASSAYS, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 463
MEXICO: TRANSPLANT DIAGNOSTICS MARKET FOR SEQUENCING-BASED MOLECULAR ASSAYS, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 464
MEXICO: TRANSPLANT DIAGNOSTICS MARKET, BY APPLICATION, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 465
MEXICO: TRANSPLANT DIAGNOSTICS MARKET FOR DIAGNOSTIC APPLICATIONS, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 466
MEXICO: TRANSPLANT DIAGNOSTICS MARKET FOR PRE-TRANSPLANTATION DIAGNOSTICS, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 467
MEXICO: TRANSPLANT DIAGNOSTICS MARKET, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 468
MEXICO: TRANSPLANT DIAGNOSTICS MARKET FOR SOLID ORGAN TRANSPLANTATION, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 469
MEXICO: TRANSPLANT DIAGNOSTICS MARKET, BY END USER, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 470
REST OF LATIN AMERICA: TRANSPLANT DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 471
REST OF LATIN AMERICA: TRANSPLANT DIAGNOSTICS MARKET, BY TECHNOLOGY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 472
REST OF LATIN AMERICA: TRANSPLANT DIAGNOSTICS MARKET FOR MOLECULAR ASSAYS, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 473
REST OF LATIN AMERICA: TRANSPLANT DIAGNOSTICS MARKET FOR PCR-BASED MOLECULAR ASSAYS, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 474
REST OF LATIN AMERICA: TRANSPLANT DIAGNOSTICS MARKET FOR SEQUENCING-BASED MOLECULAR ASSAYS, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 475
REST OF LATIN AMERICA: TRANSPLANT DIAGNOSTICS MARKET, BY APPLICATION, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 476
REST OF LATIN AMERICA: TRANSPLANT DIAGNOSTICS MARKET FOR DIAGNOSTIC APPLICATIONS, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 477
REST OF LATIN AMERICA: TRANSPLANT DIAGNOSTICS MARKET FOR PRE-TRANSPLANTATION DIAGNOSTICS, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 478
REST OF LATIN AMERICA: TRANSPLANT DIAGNOSTICS MARKET, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 479
REST OF LATIN AMERICA: TRANSPLANT DIAGNOSTICS MARKET FOR SOLID ORGAN TRANSPLANTATION, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 480
REST OF LATIN AMERICA: TRANSPLANT DIAGNOSTICS MARKET, BY END USER, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 481
MACROECONOMIC INDICATORS FOR MIDDLE EAST & AFRICA
 
 
 
 
 
 
TABLE 482
MIDDLE EAST & AFRICA: TRANSPLANT DIAGNOSTICS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 483
MIDDLE EAST & AFRICA: TRANSPLANT DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 484
MIDDLE EAST & AFRICA: TRANSPLANT DIAGNOSTICS MARKET, BY TECHNOLOGY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 485
MIDDLE EAST & AFRICA: TRANSPLANT DIAGNOSTICS MARKET FOR MOLECULAR ASSAYS, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 486
MIDDLE EAST & AFRICA: TRANSPLANT DIAGNOSTICS MARKET FOR PCR-BASED MOLECULAR ASSAYS, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 487
MIDDLE EAST & AFRICA: TRANSPLANT DIAGNOSTICS MARKET FOR SEQUENCING-BASED MOLECULAR ASSAYS, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 488
MIDDLE EAST & AFRICA: TRANSPLANT DIAGNOSTICS MARKET, BY APPLICATION, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 489
MIDDLE EAST & AFRICA: TRANSPLANT DIAGNOSTICS MARKET FOR DIAGNOSTIC APPLICATIONS, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 490
MIDDLE EAST & AFRICA: TRANSPLANT DIAGNOSTICS MARKET FOR PRE-TRANSPLANTATION DIAGNOSTICS, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 491
MIDDLE EAST & AFRICA: TRANSPLANT DIAGNOSTICS MARKET, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 492
MIDDLE EAST & AFRICA: TRANSPLANT DIAGNOSTICS MARKET FOR SOLID ORGAN TRANSPLANTATION, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 493
MIDDLE EAST & AFRICA: TRANSPLANT DIAGNOSTICS MARKET, BY END USER, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 494
UAE: TRANSPLANT DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 495
UAE: TRANSPLANT DIAGNOSTICS MARKET, BY TECHNOLOGY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 496
UAE: TRANSPLANT DIAGNOSTICS MARKET FOR MOLECULAR ASSAYS, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 497
UAE: TRANSPLANT DIAGNOSTICS MARKET FOR PCR-BASED MOLECULAR ASSAYS, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 498
UAE: TRANSPLANT DIAGNOSTICS MARKET FOR SEQUENCING-BASED MOLECULAR ASSAYS, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 499
UAE: TRANSPLANT DIAGNOSTICS MARKET, BY APPLICATION, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 500
UAE: TRANSPLANT DIAGNOSTICS MARKET FOR DIAGNOSTIC APPLICATIONS, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 501
UAE: TRANSPLANT DIAGNOSTICS MARKET FOR PRE-TRANSPLANTATION DIAGNOSTICS, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 502
UAE: TRANSPLANT DIAGNOSTICS MARKET, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 503
UAE: TRANSPLANT DIAGNOSTICS MARKET FOR SOLID ORGAN TRANSPLANTATION, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 504
UAE: TRANSPLANT DIAGNOSTICS MARKET, BY END USER, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 505
SAUDI ARABIA: TRANSPLANT DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 506
SAUDI ARABIA: TRANSPLANT DIAGNOSTICS MARKET, BY TECHNOLOGY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 507
SAUDI ARABIA: TRANSPLANT DIAGNOSTICS MARKET FOR MOLECULAR ASSAYS, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 508
SAUDI ARABIA: TRANSPLANT DIAGNOSTICS MARKET FOR PCR-BASED MOLECULAR ASSAYS, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 509
SAUDI ARABIA: TRANSPLANT DIAGNOSTICS MARKET FOR SEQUENCING-BASED MOLECULAR ASSAYS, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 510
SAUDI ARABIA: TRANSPLANT DIAGNOSTICS MARKET, BY APPLICATION, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 511
SAUDI ARABIA: TRANSPLANT DIAGNOSTICS MARKET FOR DIAGNOSTIC APPLICATIONS, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 512
SAUDI ARABIA: TRANSPLANT DIAGNOSTICS MARKET FOR PRE-TRANSPLANTATION DIAGNOSTICS, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 513
SAUDI ARABIA: TRANSPLANT DIAGNOSTICS MARKET, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 514
SAUDI ARABIA: TRANSPLANT DIAGNOSTICS MARKET FOR SOLID ORGAN TRANSPLANTATION, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 515
SAUDI ARABIA: TRANSPLANT DIAGNOSTICS MARKET, BY END USER, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 516
REST OF MIDDLE EAST & AFRICA: TRANSPLANT DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 517
REST OF MIDDLE EAST & AFRICA: TRANSPLANT DIAGNOSTICS MARKET, BY TECHNOLOGY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 518
REST OF MIDDLE EAST & AFRICA: TRANSPLANT DIAGNOSTICS MARKET FOR MOLECULAR ASSAYS, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 519
REST OF MIDDLE EAST & AFRICA: TRANSPLANT DIAGNOSTICS MARKET FOR PCR-BASED MOLECULAR ASSAYS, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 520
REST OF MIDDLE EAST & AFRICA: TRANSPLANT DIAGNOSTICS MARKET FOR SEQUENCING-BASED MOLECULAR ASSAYS, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 521
REST OF MIDDLE EAST & AFRICA: TRANSPLANT DIAGNOSTICS MARKET, BY APPLICATION, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 522
REST OF MIDDLE EAST & AFRICA: TRANSPLANT DIAGNOSTICS MARKET FOR DIAGNOSTIC APPLICATIONS, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 523
REST OF MIDDLE EAST & AFRICA: TRANSPLANT DIAGNOSTICS MARKET FOR PRE-TRANSPLANTATION DIAGNOSTICS, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 524
REST OF MIDDLE EAST & AFRICA: TRANSPLANT DIAGNOSTICS MARKET, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 525
REST OF MIDDLE EAST & AFRICA: TRANSPLANT DIAGNOSTICS MARKET FOR SOLID ORGAN TRANSPLANTATION, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 526
REST OF MIDDLE EAST & AFRICA: TRANSPLANT DIAGNOSTICS MARKET, BY END USER, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 527
US: HEART, LIVER, AND LUNG TRANSPLANTS MARKET, BY TYPE, 2024–2031 (IN THOUSAND)
 
 
 
 
 
 
TABLE 528
OVERVIEW OF STRATEGIES DEPLOYED BY KEY COMPANIES IN TRANSPLANT DIAGNOSTICS MARKET, JANUARY 2023−APRIL 2026
 
 
 
 
 
 
TABLE 529
TRANSPLANT DIAGNOSTICS MARKET: DEGREE OF COMPETITION
 
 
 
 
 
 
TABLE 530
TRANSPLANT DIAGNOSTICS MARKET: REGION FOOTPRINT
 
 
 
 
 
 
TABLE 531
TRANSPLANT DIAGNOSTICS MARKET: PRODUCT & SERVICE FOOTPRINT
 
 
 
 
 
 
TABLE 532
TRANSPLANT DIAGNOSTICS MARKET: APPLICATION FOOTPRINT
 
 
 
 
 
 
TABLE 533
TRANSPLANT DIAGNOSTICS MARKET: END-USER FOOTPRINT
 
 
 
 
 
 
TABLE 534
TRANSPLANT DIAGNOSTICS MARKET: DETAILED LIST OF KEY STARTUPS/SMES
 
 
 
 
 
 
TABLE 535
TRANSPLANT DIAGNOSTICS MARKET: COMPETITIVE BENCHMARKING OF STARTUPS/SMES (1/2)
 
 
 
 
 
 
TABLE 536
TRANSPLANT DIAGNOSTICS MARKET: COMPETITIVE BENCHMARKING OF STARTUPS/SMES (2/2)
 
 
 
 
 
 
TABLE 537
TRANSPLANT DIAGNOSTICS MARKET: PRODUCT/SERVICE LAUNCHES & APPROVALS, JANUARY 2023–APRIL 2026
 
 
 
 
 
 
TABLE 538
TRANSPLANT DIAGNOSTICS MARKET: DEALS, JANUARY 2023–APRIL 2026
 
 
 
 
 
 
TABLE 539
TRANSPLANT DIAGNOSTICS MARKET: EXPANSION, JANUARY 2023–APRIL 2026
 
 
 
 
 
 
TABLE 540
THERMO FISHER SCIENTIFIC INC.: COMPANY OVERVIEW
 
 
 
 
 
 
TABLE 541
THERMO FISHER SCIENTIFIC INC.: PRODUCTS OFFERED
 
 
 
 
 
 
TABLE 542
THERMO FISHER SCIENTIFIC INC.: PRODUCT & SERVICE LAUNCHES, JANUARY 2023–APRIL 2026
 
 
 
 
 
 
TABLE 543
THERMO FISHER SCIENTIFIC INC.: DEALS, JANUARY 2023–APRIL 2026
 
 
 
 
 
 
TABLE 544
THERMO FISHER SCIENTIFIC INC.: EXPANSIONS, JANUARY 2022–APRIL 2025
 
 
 
 
 
 
TABLE 545
F. HOFFMANN-LA ROCHE LTD.: COMPANY OVERVIEW
 
 
 
 
 
 
TABLE 546
F. HOFFMANN-LA ROCHE LTD.: PRODUCTS OFFERED
 
 
 
 
 
 
TABLE 547
F. HOFFMANN-LA ROCHE LTD.: PRODUCT LAUNCHES & APPROVALS, JANUARY 2023–APRIL 2026
 
 
 
 
 
 
TABLE 548
F. HOFFMANN-LA ROCHE LTD.: DEALS, JANUARY 2023–APRIL 2026
 
 
 
 
 
 
TABLE 549
BIO-RAD LABORATORIES, INC.: COMPANY OVERVIEW
 
 
 
 
 
 
TABLE 550
BIO-RAD LABORATORIES, INC.: PRODUCTS OFFERED
 
 
 
 
 
 
TABLE 551
BIO-RAD LABORATORIES, INC.: PRODUCT LAUNCHES, JANUARY 2023–APRIL 2026
 
 
 
 
 
 
TABLE 552
BIO-RAD LABORATORIES, INC.: DEALS, JANUARY 2023–APRIL 2026
 
 
 
 
 
 
TABLE 553
QIAGEN N.V.: COMPANY OVERVIEW
 
 
 
 
 
 
TABLE 554
QIAGEN N.V.: PRODUCTS OFFERED
 
 
 
 
 
 
TABLE 555
QIAGEN N.V.: PRODUCT LAUNCHES & APPROVALS, JANUARY 2023–APRIL 2026
 
 
 
 
 
 
TABLE 556
QIAGEN N.V.: DEALS, JANUARY 2023–APRIL 2026
 
 
 
 
 
 
TABLE 557
BIOMÉRIEUX: COMPANY OVERVIEW
 
 
 
 
 
 
TABLE 558
BIOMÉRIEUX: PRODUCTS OFFERED
 
 
 
 
 
 
TABLE 559
BIOMÉRIEUX: PRODUCT LAUNCHES & APPROVALS, JANUARY 2023–APRIL 2026
 
 
 
 
 
 
TABLE 560
BIOMÉRIEUX: DEALS, JANUARY 2023–APRIL 2026
 
 
 
 
 
 
TABLE 561
ILLUMINA, INC.: COMPANY OVERVIEW
 
 
 
 
 
 
TABLE 562
ILLUMINA, INC.: PRODUCTS OFFERED
 
 
 
 
 
 
TABLE 563
ILLUMINA, INC.: DEALS, JANUARY 2023–APRIL 2026
 
 
 
 
 
 
TABLE 564
BECTON, DICKINSON AND COMPANY: COMPANY OVERVIEW
 
 
 
 
 
 
TABLE 565
BECTON, DICKINSON AND COMPANY: PRODUCTS OFFERED
 
 
 
 
 
 
TABLE 566
BECTON, DICKINSON AND COMPANY: DEALS, JANUARY 2023–APRIL 2026
 
 
 
 
 
 
TABLE 567
CAREDX, INC.: COMPANY OVERVIEW
 
 
 
 
 
 
TABLE 568
CAREDX, INC.: PRODUCTS OFFERED
 
 
 
 
 
 
TABLE 569
CAREDX, INC.: PRODUCT LAUNCHES, JANUARY 2023–APRIL 2026
 
 
 
 
 
 
TABLE 570
CAREDX, INC.: DEALS, JANUARY 2023–APRIL 2026
 
 
 
 
 
 
TABLE 571
DIASORIN S.P.A.: COMPANY OVERVIEW
 
 
 
 
 
 
TABLE 572
DIASORIN S.P.A.: PRODUCTS OFFERED
 
 
 
 
 
 
TABLE 573
DIASORIN S.P.A.: PRODUCT LAUNCHES, JANUARY 2023–APRIL 2026
 
 
 
 
 
 
TABLE 574
DIASORIN S.P.A.: DEALS, JANUARY 2023–APRIL 2026
 
 
 
 
 
 
TABLE 575
WERFEN: COMPANY OVERVIEW
 
 
 
 
 
 
TABLE 576
WERFEN: PRODUCTS OFFERED
 
 
 
 
 
 
TABLE 577
WERFEN: PRODUCT LAUNCHES, JANUARY 2023–APRIL 2026
 
 
 
 
 
 
TABLE 578
WERFEN: DEALS, JANUARY 2023–APRIL 2026
 
 
 
 
 
 
TABLE 579
MERCK KGAA: COMPANY OVERVIEW
 
 
 
 
 
 
TABLE 580
MERCK KGAA: PRODUCTS OFFERED
 
 
 
 
 
 
TABLE 581
MERCK KGAA: DEALS, JANUARY 2023–APRIL 2026
 
 
 
 
 
 
TABLE 582
MERCK KGAA: EXPANSIONS, JANUARY 2023–APRIL 2026
 
 
 
 
 
 
TABLE 583
HOLOGIC, INC.: COMPANY OVERVIEW
 
 
 
 
 
 
TABLE 584
HOLOGIC, INC.: PRODUCTS OFFERED
 
 
 
 
 
 
TABLE 585
EUROBIO SCIENTIFIC: COMPANY OVERVIEW
 
 
 
 
 
 
TABLE 586
BIOFORTUNA LIMITED: COMPANY OVERVIEW
 
 
 
 
 
 
TABLE 587
BAG DIAGNOSTICS GMBH: COMPANY OVERVIEW
 
 
 
 
 
 
TABLE 588
FUJIREBIO: COMPANY OVERVIEW
 
 
 
 
 
 
TABLE 589
HISTOGENETICS LLC: COMPANY OVERVIEW
 
 
 
 
 
 
TABLE 590
PACBIO: COMPANY OVERVIEW
 
 
 
 
 
 
TABLE 591
TBG BIOTECHNOLOGY CORP: COMPANY OVERVIEW
 
 
 
 
 
 
TABLE 592
SCISCO GENETICS, INC.: COMPANY OVERVIEW
 
 
 
 
 
 
TABLE 593
INNO-TRAIN DIAGNOSTIK GMBH: COMPANY OVERVIEW
 
 
 
 
 
 
TABLE 594
BIONOBIS: COMPANY OVERVIEW
 
 
 
 
 
 
TABLE 595
TAKARA BIO INC.: COMPANY OVERVIEW
 
 
 
 
 
 
TABLE 596
KRISHGEN BIOSYSTEMS PRIVATE LIMITED: COMPANY OVERVIEW
 
 
 
 
 
 
TABLE 597
PROIMMUNE LTD.: COMPANY OVERVIEW
 
 
 
 
 
 
TABLE 598
TRANSPLANT DIAGNOSTICS MARKET: RISK ASSESSMENT
 
 
 
 
 
 
LIST OF FIGURES
 
 
 
 
 
 
 
FIGURE 1
TRANSPLANT DIAGNOSTICS MARKET SEGMENTATION & REGIONAL SCOPE
 
 
 
 
 
 
FIGURE 2
KEY INSIGHTS & MARKET HIGHLIGHTS
 
 
 
 
 
 
FIGURE 3
GLOBAL TRANSPLANT DIAGNOSTICS MARKET, 2024–2031
 
 
 
 
 
 
FIGURE 4
MAJOR STRATEGIES ADOPTED BY KEY PLAYERS IN TRANSPLANT DIAGNOSTICS MARKET, 2023–2025
 
 
 
 
 
 
FIGURE 5
DISRUPTIVE TRENDS IMPACTING GROWTH OF TRANSPLANT DIAGNOSTICS MARKET
 
 
 
 
 
 
FIGURE 6
HIGH-GROWTH SEGMENTS & EMERGING FRONTIERS IN TRANSPLANT DIAGNOSTICS MARKET, 2025
 
 
 
 
 
 
FIGURE 7
ASIA PACIFIC TO REGISTER HIGHEST GROWTH DURING FORECAST PERIOD
 
 
 
 
 
 
FIGURE 8
RISING CASES OF INFECTIOUS DISEASES TO DRIVE MARKET
 
 
 
 
 
 
FIGURE 9
REAGENTS & CONSUMABLES SEGMENT TO DOMINATE MARKET DURING FORECAST PERIOD
 
 
 
 
 
 
FIGURE 10
MOLECULAR ASSAYS SEGMENT TO LEAD MARKET DURING FORECAST PERIOD
 
 
 
 
 
 
FIGURE 11
DIAGNOSTIC APPLICATIONS SEGMENT TO LEAD MARKET DURING FORECAST PERIOD
 
 
 
 
 
 
FIGURE 12
SOLID ORGAN TRANSPLANTATION SEGMENT TO DOMINATE MARKET DURING FORECAST PERIOD
 
 
 
 
 
 
FIGURE 13
INDEPENDENT REFERENCE LABORATORIES SEGMENT TO LEAD MARKET DURING FORECAST PERIOD
 
 
 
 
 
 
FIGURE 14
ASIA PACIFIC TO REGISTER HIGHEST GROWTH DURING FORECAST PERIOD
 
 
 
 
 
 
FIGURE 15
TRANSPLANT DIAGNOSTICS MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES
 
 
 
 
 
 
FIGURE 16
TRANSPLANT DIAGNOSTICS MARKET: PORTER’S FIVE FORCES ANALYSIS
 
 
 
 
 
 
FIGURE 17
TRANSPLANT DIAGNOSTICS MARKET: SUPPLY CHAIN ANALYSIS
 
 
 
 
 
 
FIGURE 18
TRANSPLANT DIAGNOSTICS MARKET: VALUE CHAIN ANALYSIS
 
 
 
 
 
 
FIGURE 19
TRANSPLANT DIAGNOSTICS MARKET: ECOSYSTEM ANALYSIS
 
 
 
 
 
 
FIGURE 20
TRANSPLANT DIAGNOSTICS MARKET: TRENDS & DISRUPTIONS IMPACTING CUSTOMERS’ BUSINESSES
 
 
 
 
 
 
FIGURE 21
NUMBER OF DEALS & FUNDING ACTIVITIES IN TRANSPLANT DIAGNOSTICS MARKET
 
 
 
 
 
 
FIGURE 22
PATENT ANALYSIS FOR TRANSPLANT DIAGNOSTICS, JANUARY 2016–DECEMBER 2025
 
 
 
 
 
 
FIGURE 23
MARKET POTENTIAL OF AI IN TRANSPLANT DIAGNOSTICS MARKET
 
 
 
 
 
 
FIGURE 24
INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS, BY PRODUCT & SERVICE
 
 
 
 
 
 
FIGURE 25
KEY BUYING CRITERIA, BY PRODUCT & SERVICE
 
 
 
 
 
 
FIGURE 26
NORTH AMERICA: TRANSPLANT DIAGNOSTICS MARKET SNAPSHOT
 
 
 
 
 
 
FIGURE 27
ASIA PACIFIC: TRANSPLANT DIAGNOSTICS MARKET SNAPSHOT
 
 
 
 
 
 
FIGURE 28
REVENUE ANALYSIS OF KEY PLAYERS IN TRANSPLANT DIAGNOSTICS MARKET, 2023–2025 (USD MILLION)
 
 
 
 
 
 
FIGURE 29
TRANSPLANT DIAGNOSTICS MARKET SHARE ANALYSIS, 2025 (GLOBAL)
 
 
 
 
 
 
FIGURE 30
TRANSPLANT DIAGNOSTICS MARKET: COMPANY EVALUATION MATRIX (KEY PLAYERS), 2025
 
 
 
 
 
 
FIGURE 31
TRANSPLANT DIAGNOSTICS MARKET: COMPANY FOOTPRINT
 
 
 
 
 
 
FIGURE 32
TRANSPLANT DIAGNOSTICS MARKET: COMPANY EVALUATION MATRIX (STARTUPS/SMES), 2025
 
 
 
 
 
 
FIGURE 33
EV/EBITDA OF KEY VENDORS
 
 
 
 
 
 
FIGURE 34
YEAR-TO-DATE (YTD) PRICE TOTAL RETURN AND 5-YEAR STOCK BETA OF KEY VENDORS
 
 
 
 
 
 
FIGURE 35
TRANSPLANT DIAGNOSTICS MARKET: BRAND/PRODUCT COMPARISON FOR TRANSPLANT INSTRUMENTS
 
 
 
 
 
 
FIGURE 36
THERMO FISHER SCIENTIFIC INC.: COMPANY SNAPSHOT (2025)
 
 
 
 
 
 
FIGURE 37
F. HOFFMANN-LA ROCHE LTD.: COMPANY SNAPSHOT (2025)
 
 
 
 
 
 
FIGURE 38
BIO-RAD LABORATORIES, INC.: COMPANY SNAPSHOT (2025)
 
 
 
 
 
 
FIGURE 39
QIAGEN N.V.: COMPANY SNAPSHOT (2025)
 
 
 
 
 
 
FIGURE 40
BIOMÉRIEUX: COMPANY SNAPSHOT (2025)
 
 
 
 
 
 
FIGURE 41
ILLUMINA, INC.: COMPANY SNAPSHOT (2025)
 
 
 
 
 
 
FIGURE 42
BECTON, DICKINSON AND COMPANY: COMPANY SNAPSHOT (2025)
 
 
 
 
 
 
FIGURE 43
CAREDX, INC.: COMPANY SNAPSHOT (2025)
 
 
 
 
 
 
FIGURE 44
DIASORIN S.P.A.: COMPANY SNAPSHOT (2025)
 
 
 
 
 
 
FIGURE 45
WERFEN: COMPANY SNAPSHOT (2025)
 
 
 
 
 
 
FIGURE 46
MERCK KGAA: COMPANY SNAPSHOT (2025)
 
 
 
 
 
 
FIGURE 47
HOLOGIC, INC.: COMPANY SNAPSHOT (2025)
 
 
 
 
 
 
FIGURE 48
RESEARCH DESIGN
 
 
 
 
 
 
FIGURE 49
BREAKDOWN OF PRIMARY INTERVIEWS: BY COMPANY TYPE, DESIGNATION, AND REGION
 
 
 
 
 
 
FIGURE 50
TOP-DOWN APPROACH
 
 
 
 
 
 
FIGURE 51
DATA TRIANGULATION
 
 
 
 
 
 

 

Methodology

The objective of this study is to analyze the key market dynamics, including drivers, opportunities, constraints, challenges, and strategies employed by key players. We will track developments within companies, such as acquisitions, product launches, expansions, agreements, and partnerships, to assess the competitive landscape of the transplant diagnostics market. This analysis will evaluate market players across various parameters within the broader categories of business and product strategy.

To estimate the market size, both top-down and bottom-up approaches were utilized. The market breakdown and data triangulation were employed to determine the sizes of segments and subsegments.

The four steps involved in estimating the market size are:

Secondary Research

In the secondary research process, various secondary sources such as annual reports, press releases & investor presentations of companies, white papers, certified publications, articles by recognized authors, gold-standard & silver-standard websites, regulatory bodies, and databases (such as D&B Hoovers, Bloomberg Business, and Factiva) were referred to identify and collect information for this study.

Primary Research

In the primary research process, various sources from both the supply and demand sides were interviewed to obtain qualitative and quantitative information for this report. Primary sources were mainly industry experts from the core and related industries, as well as preferred suppliers, manufacturers, distributors, service providers, technology developers, researchers, and organizations across all segments of this industry’s value chain. In-depth interviews were conducted with various primary respondents, including key industry participants, subject-matter experts, C-level executives at key market players, and industry consultants, to obtain and verify critical qualitative and quantitative information and to assess prospects.

The following is the breakdown of primary respondents:

Transplant Diagnostics Market Size, and Share

Note 1: Other designations include sales, marketing, and product managers.
Note 2: Companies are classified into tiers based on their total revenues. As of 2025, Tier 1 = >USD 100 million, Tier 2 = USD 10 million to USD 100 million, and Tier 3 = <USD 10 million.


COMPANY NAME

DESIGNATION

Thermo Fisher Scientific Inc. (US)

Sales Manager

F. Hoffmann-La Roche AG (Switzerland)

Product Manager

To know about the assumptions considered for the study, download the pdf brochure

Market Size Estimation

Both top-down and bottom-up approaches were used to estimate and validate the total size of the transplant diagnostics market. These methods were also used extensively to estimate the size of various subsegments in the market. The research methodology used to estimate the market size includes the following:

  • The key players in the industry have been identified through extensive secondary research.
  • The revenues generated by leading players operating in the transplant diagnostics market have been determined through primary and secondary research.
  • All percentage shares, splits, and breakdowns have been determined using secondary sources and verified through primary sources.

The research methodology used to estimate the market size includes the following:

Transplant Diagnostics Market : Top-Down and Bottom-Up Approach

Transplant Diagnostics Market Top Down and Bottom Up Approach

Data Triangulation

After arriving at the overall market size by applying the process mentioned above, the total market was split into several segments and subsegments. To complete the overall market engineering process and arrive at the exact statistics for all segments and subsegments, data triangulation and market breakdown procedures were employed, wherever applicable. The data was triangulated by studying various factors and trends from both the demand and supply sides.

Market Definition

Transplant diagnostic procedures are used to determine donor-recipient compatibility to avoid the risk of immune rejection in a recipient. These procedures are adopted for donor-recipient cross-matching, subject profiling, genotyping, and other related diagnostic tests. Advanced genomic techniques (such as PCR and NGS) are increasingly being used during transplant diagnostic procedures, apart from serological and other conventional techniques for immuno-compatibility testing (such as antibody-antigen reaction and leucocyte assay).

Key Stakeholders

  • To define, segment, and forecast the transplant diagnostics market by product & service, technology, application, type, end user, and region
  • To provide detailed information regarding the major factors influencing market growth (such as drivers, restraints, opportunities, and challenges)
  • To analyze micromarkets with respect to individual growth trends, prospects, and contributions to the overall market 
  • To analyze market opportunities for stakeholders and provide details of the competitive landscape for key players
  • To forecast the size of the market segments with respect to five regions: North America, Europe, the Asia Pacific, Latin America, and the Middle East & Africa.
  • To profile key players and comprehensively analyze their product portfolios, market positions, and core competencies
  • To benchmark players within the market using the proprietary Company Evaluation Matrix framework, which analyzes market players on various parameters within the broad categories of business and product excellence
  • To study the impact of AI on the market, along with the macroeconomic outlook for each region

Report Objectives

  • To define, segment, and forecast the transplant diagnostics market by product & service, technology, application, type, end user, and region
  • To provide detailed information regarding the major factors influencing market growth (such as drivers, restraints, opportunities, and challenges)
  • To analyze micromarkets with respect to individual growth trends, prospects, and contributions to the overall market 
  • To analyze market opportunities for stakeholders and provide details of the competitive landscape for key players
  • To forecast the size of the market segments with respect to five regions: North America, Europe, the Asia Pacific, Latin America, and the Middle East & Africa.
  • To profile key players and comprehensively analyze their product portfolios, market positions, and core competencies
  • To benchmark players within the market using the proprietary Company Evaluation Matrix framework, which analyzes market players on various parameters within the broad categories of business and product excellence
  • To study the impact of AI on the market, along with the macroeconomic outlook for each region

Available customizations:

MarketsandMarkets offers the following customizations for this market report.

Product Analysis

 

  • Product matrix, which provides a detailed comparison of the product portfolio of each company in the transplant diagnostics market

Country Information

 

  • Product matrix, which provides a detailed comparison of the product portfolio of each company in the transplant diagnostics market

Company Profiles

 

  • Product matrix, which provides a detailed comparison of the product portfolio of each company in the transplant diagnostics market

 

TABLE OF CONTENTS

METHODOLOGY

Need a Tailored Report?

Customize this report to your needs

Get 10% FREE Customization

Customize This Report
Fact checked
Cite this Research

Adjacent Markets

Request Bundle Reports

Personalize This Research

  • Triangulate with your Own Data
  • Get Data as per your Format and Definition
  • Gain a Deeper Dive on a Specific Application, Geography, Customer or Competitor
  • Any level of Personalization
Request A Free Customisation

Let Us Help You

  • What are the Known and Unknown Adjacencies Impacting the Transplant Diagnostics Market
  • What will your New Revenue Sources be?
  • Who will be your Top Customer; what will make them switch?
  • Defend your Market Share or Win Competitors
  • Get a Scorecard for Target Partners
Customized Workshop Request
Forbes

Custom Market Research Services

We Will Customise The Research For You, In Case The Report Listed Above Does Not Meet With Your Requirements

Get 10% Free Customisation

TESTIMONIALS

Growth opportunities and latent adjacency in Transplant Diagnostics Market

DMCA.com Protection Status